



- (51) International Patent Classification:  
C12N 15/86 (2006.01)
- (21) International Application Number:  
PCT/US2022/024478
- (22) International Filing Date:  
12 April 2022 (12.04.2022)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
63/173,527 12 April 2021 (12.04.2021) US

MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


- (71) Applicant: **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 1111 Franklin Street, 5th Floor, Oakland, California 94607-5200 (US).
- (72) Inventors: **SHEIKH, Farah**; 3130 Hamburg Square, San Diego, California 92037 (US). **BRADFORD, William**; 930 Via Mil Cumbres, Unit 176, Solana Beach, California 92075 (US).
- (74) Agent: **WARREN, William L.** et al.; EVERSHEDS SUTHERLAND (US) LLP, 999 Peachtree Street, NE, Atlanta, Georgia 30309-3996 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**  
— with international search report (Art. 21(3))  
— with sequence listing part of description (Rule 5.2(a))

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,

(54) Title: GENE THERAPY FOR ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY



**FIG. 1A**

(57) Abstract: Compositions and methods for preventing and treating cardiac arrhythmia. Methods of preventing or treating arrhythmogenic right ventricular cardiomyopathy (ARVC), comprising administering to a subject in need a prophylactic or treatment effective amount of a composition comprising a plakophilin-2 (PKP2) gene. The composition further comprises an adenovirus-associated vector (AAV) to deliver the PKP-2 gene. In embodiments, the invention provides that the AAV is a cardiotropic AAV serotype and contains a cardiac-specific promoter. Method of treating a cardiovascular disease characterized by abnormal cardiac cell-cell junction complex comprising administering to a subject in need a prophylactic or treatment effective amount of a composition comprising a plakophilin-2 (PKP2) gene.

WO 2022/221320 A1

**GENE THERAPY FOR ARRHYTHMOGENIC RIGHT VENTRICULAR  
CARDIOMYOPATHY**

5 **CROSS-REFERENCE TO RELATED APPLICATIONS**

[0001] The application claims priority to, and the benefit of, U.S. Provisional Application No. 63/173,527 filed April 12, 2021. The contents of this application is hereby incorporated by reference in their entirety.

10 **INCORPORATION BY REFERENCE OF SEQUENCE LISTING**

[0002] The contents of the text file named “24978-0711\_SeqList\_ST25”, which was created on April 12, 2022 and is 89 KB in size, are hereby incorporated by reference in their entirety.

15 **GOVERNMENT SPONSORSHIP**

[0003] This invention was made with government support under grant No. HL142251 awarded by the National Institutes of Health. The government has certain rights in the invention.

20 **INCORPORATION BY REFERENCE OF SEQUENCE LISTING**

[0004] The contents of the text file named “XXXX”, which was created on XXX and is XXX KB in size, are hereby incorporated by reference in their entirety.

**TECHNICAL FIELD**

25 [0005] The present invention relates to gene therapy for arrhythmogenic right ventricular cardiomyopathy (ARVC).

**BACKGROUND**

[0006] To date there are no effective treatments or cures for arrhythmogenic right ventricular cardiomyopathy (ARVC), as well as no randomized clinical trials of treatment modalities, screening regimens or medications specific for ARVC (1). Current approaches are directed at symptomatic relief and centered around lifestyle change (avoiding competitive sports that can trigger sudden cardiac death) and pharmacological intervention (anti-arrhythmic drugs, beta-blockers) (2,3). These approaches may transition into more invasive actions, which include implantable cardioverter-defibrillators (ICDs), cardiac catheter ablation, or heart transplantation if a patient becomes unresponsive or intolerant to  
35

pharmacotherapies (2,3). ICDs have frequent device/lead related complications, catheter ablations are subject to recurrence due to the generation of new arrhythmogenic foci, and heart transplantation has a 23% mortality rate 10 years post-procedure (3). These factors highlight the critical need to identify new prophylactic and therapeutic strategies that can target the molecular triggers (cell-cell junction disruption) of ARVC as a means to prevent or halt disease progression.

### SUMMARY

10 [0007] The disclosure provides a recombinant adeno-associated virus (rAAV) vector comprising in 5' to 3' direction: a) a first AAV ITR sequence; b) a promoter sequence; c) a transgene nucleic acid molecule, wherein the transgene nucleic acid molecule comprises a nucleic acid sequence encoding for a plakophilin-2 (PKP2) polypeptide; d) a post-transcriptional regulatory element; e) a polyA sequence; and f) a second AAV ITR  
15 sequence.

[0008] The disclosure provides an rAAV vector comprising the nucleic acid sequence set forth in SEQ ID NO: 9, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 29, or SEQ ID NO: 30.

20 [0009] In some aspects, the PKP2 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 13.

[0010] In some aspects, the nucleic acid sequence encoding for a PKP2 polypeptide comprises the nucleic acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 14.

[0011] In some aspects, the first AAV ITR sequence comprises the nucleic acid sequence set forth in SEQ ID NO: 7, SEQ ID NO, 8, SEQ ID NO: 15, SEQ ID NO: 15, SEQ  
25 ID NO: 19, SEQ ID NO: 20, or SEQ ID NO: 25. In some aspects, the second AAV ITR sequence comprises the nucleic acid sequence set forth in SEQ ID NO: 7, SEQ ID NO, 8, SEQ ID NO: 15, SEQ ID NO: 15, SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO: 25.

[0012] In some aspects, the promoter sequence is a cardiac-specific promoter sequence.

30 [0013] In some aspects, the promoter sequence comprises a Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), a cytomegalovirus (CMV) promoter, an SV40 promoter, a dihydrofolate reductase promoter, a beta-actin promoter, a phosphoglycerol kinase (PGK) promoter, a U6 promoter, an H1 promoter, a CAG promoter, a hybrid chicken  $\beta$ -actin promoter, an MeCP2 promoter, an EF1 promoter, a ubiquitous

chicken  $\beta$ -actin hybrid (CBh) promoter, a U1a promoter, a U1b promoter, an MeCP2 promoter, an MeP418 promoter, an MeP426 promoter, a minimal MeCP2 promoter, a VMD2 promoter, an mRho promoter, EFla promoter, Ubc promoter, human  $\beta$ -actin promoter, TRE promoter, Ac5 promoter, Polyhedrin promoter, CaMKIIa promoter, Gal1  
5 promoter, TEF1 promoter, GDS promoter, ADH1 promoter, Ubi promoter, or  $\alpha$ -1-antitrypsin (hAAT) promoter. In some aspects, the promoter sequence comprises a cardiac troponin T (cTnT) promoter sequence. In some aspects, the cTnT promoter sequence comprises the nucleic acid sequence set forth in SEQ ID NO: 2.

[0014] In some aspects, the polyA sequence comprises a rabbit beta-globin polyA  
10 sequence. In some aspects, the rabbit beta-globin polyA sequence comprises the nucleic acid sequence set forth in SEQ ID NO: 6.

[0015] In some aspects, the post-transcriptional regulatory element is an oPRE post-transcriptional regulatory element. In some aspects, the oPRE post-transcriptional regulatory element comprises the nucleic acid sequence set forth in SEQ ID NO: 5, SEQ ID  
15 NO: 27, or SEQ ID NO: 28.

The disclosure provides an rAAV vector of any one of the preceding claims, comprising, in the 5' to 3' direction: a) a first AAV ITR sequence comprising the nucleic acid sequence set forth in SEQ ID NO: 7; b) a promoter sequence comprising the nucleic acid sequence set forth in SEQ ID NO: 2; c) a transgene nucleic acid molecule, wherein the transgene nucleic acid molecule comprises a nucleic acid sequence encoding for a PKP2 polypeptide, wherein the nucleic acid sequence encoding for a PKP2 polypeptide comprises the nucleic acid sequence set forth in SEQ ID NO: 4; d) a post-transcriptional regulatory element comprising the nucleic acid sequence set forth in SEQ ID NO: 5; e) a polyA sequence comprising the nucleic acid sequence set forth in SEQ ID NO: 6; and f) a second AAV ITR sequence  
20 comprising the nucleic acid sequence set forth in SEQ ID NO: 8.

[0016] The disclosure provides an rAAV viral vector comprising (i) an AAV capsid protein; and (ii) an rAAV vector of any one of the preceding claims.

[0017] In some aspects, the AAV capsid protein is an AAV1 capsid protein, an AAV2 capsid protein, an AAV4 capsid protein, an AAV5 capsid protein, an AAV6 capsid protein, an AAV7 capsid protein, an AAV8 capsid protein, an AAV9 capsid protein, an AAV10 capsid protein, an AAV11 capsid protein, an AAV12 capsid protein, an AAV13 capsid protein, an AAVPHP.B capsid protein, an AAVrh74 capsid protein or an AAVrh10  
30

capsid protein. In some aspects, the AAV capsid protein is an AAV9 or AAVrh10 capsid protein.

5 [0018] The disclosure provides a pharmaceutical composition comprising: a) the rAAV viral vector of any embodiment of the disclosure; and at least one pharmaceutically acceptable excipient and/or additive.

[0019] The disclosure provides a method for treating a subject having a disease and/or disorder involving a *PKP2* gene, the method comprising administering to the subject at least one therapeutically effective amount of the rAAV viral vector of any embodiment of the disclosure or the pharmaceutical composition of any embodiment of the disclosure.

10 [0020] In some aspects, the disease and/or disorder involving a *PKP2* gene is a cardiovascular disease characterized by abnormal cardiac cell-cell junction complexes.

[0021] In some aspects, the disease and/or disorder involving a *PKP2* gene is arrhythmogenic right ventricular cardiomyopathy (ARVC).

15 [0022] In some aspects, the effective amount improves electrical and structural cardiac integrity in the subject. In some aspects, the effective amount rescues and reassembles cell-cell junction proteins in the subject. In some aspects, the effective amount improves cardiac function in the subject. In some aspects, the effective amount preserves electrical and structural integrity to prevent ARVC in the subject.

20 [0023] In some aspects, the rAAV viral vector or the pharmaceutical composition is administered to the subject at a dose ranging from about  $1.0 \times 10^{12}$  vg/kg to about  $2.5 \times 10^{14}$  vg/kg. In some aspects, the rAAV viral vector or the pharmaceutical composition is administered to the subject at a dose ranging from about  $1.0 \times 10^{12}$  vg/kg to about  $5.0 \times 10^{13}$  vg/kg.

25 [0024] In some aspects, the rAAV viral vector or the pharmaceutical composition is administered to the subject intravenously, intrathecally, intracerebrally, intraventricularly, intranasally, intratracheally, intra-aurally, intra-ocularly, or peri-ocularly, orally, rectally, transmucosally, inhalationally, transdermally, parenterally, subcutaneously, intradermally, intramuscularly, intracisternally, intranervally, intrapleurally, topically, intralymphatically, intracisternally or intranerve.

30 [0025] In some aspects, the rAAV viral vector of any one of the embodiments of the disclosure or the pharmaceutical composition of any embodiment of the disclosure for use in treating a disease and/or disorder involving a *PKP2* gene in a subject in need thereof.

[0026] In some aspects, the disease and/or disorder involving a *PKP2* gene is ARVC.

[0027] In some aspects, the rAAV viral vector or the pharmaceutical composition is for administration to the subject at a dose ranging from about  $1.0 \times 10^{12}$  vg/kg to about 5 2.5x10<sup>14</sup> vg/kg. In some aspects, the rAAV viral vector or the pharmaceutical composition is for administration to the subject at a dose ranging from about  $1.0 \times 10^{12}$  vg/kg to about 5.0x10<sup>13</sup> vg/kg.

[0028] In some aspects, the rAAV viral vector or the pharmaceutical composition is for administration to the subject intravenously, intrathecally, intracerebrally, 10 intraventricularly, intranasally, intratracheally, intra-aurally, intra-ocularly, or peri-ocularly, orally, rectally, transmucosally, inhalationally, transdermally, parenterally, subcutaneously, intradermally, intramuscularly, intracisternally, intranervally, intrapleurally, topically, intralymphatically, intracisternally or intranerve. In some aspects, the rAAV viral vector or pharmaceutical composition is for administration intravenously.

15

#### BRIEF DESCRIPTION OF THE DRAWINGS

[0029] FIGS. 1A-1C show Adeno(-associated) virus technology can stably express PKP2 protein. FIG. 1A shows a western blot analysis of mutant (MUT) and wild type (WT) PKP2 protein following adenovirus transduction of neonatal cardiomyocytes at indicated 20 multiplicities of infection (MOI). FLAG antibody recognizes PKP2 and GAPDH serves as the loading control. FIG. 1B shows a schematic for early intraperitoneal injection of AAV9 PKP2 at postnatal day 2 (P2) in wild type (WT) mice and analysis of hearts 4 weeks later. FIG. 1C shows a western blot analysis of PKP2 protein following AAV9 PKP2 injection at postnatal day 2 (P2). PKP2 antibody recognizes endogenous and transduced PKP2, FLAG 25 antibody recognizes only transduced PKP2, and GAPDH serves as the loading control.

[0030] FIG. 2 shows elevating PKP2 protein dose in vitro reassembles the cardiac cell-cell junction. Western blot analysis of desmosomal (PKP2, DSP, DSG2, JUP), fascia-adherens (N-Cad), and gap junction (CX43) proteins following transduction of PKP2 homozygous mutant neonatal cardiomyocytes (Hom CM) with either wild type (WT) or 30 mutant (MUT) PKP2 adenovirus. GAPDH serves as the loading control.

[0031] FIGS. 3A-3C show early AAV9 PKP2 administration restores the cardiac cell-cell junction and improves cardiac morphology. FIG. 3A shows a schematic for early intraperitoneal injection of AAV9 PKP2 at postnatal day 2 (P2) in PKP2 homozygous

mutant (PKP2 Hom) mice and analysis of hearts 4 weeks later. FIG. 3B shows a western blot analysis of control (Ctrl), PKP2 Hom hearts treated with AAV9-PKP2, and PKP2 Hom hearts with no virus treatment for desmosomal proteins (PKP2, DSP, DSG2, JUP), fascia-adherens protein (N-CAD), and gap junction protein (CX43). GAPDH serves as the loading control. FIG. 3C shows a heart weight (HW) to body weight (BW) ratio analysis of control (Ctrl), untreated PKP2 homozygous mutant (Hom) hearts, and PKP2 Hom hearts treated with AAV9-PKP2. Mean values with standard deviation. n=5 Ctrl, n=5 Hom, n=3 Hom-AAV9 PKP2. One-way ANOVA with Tukey post hoc test. \*\*, p<0.01.

[0032] FIGS. 4A-4E show an Early AAV9 PKP2 administration prevents cardiac mechanical and electrical dysfunction. FIG. 4A shows a representative short-axis cardiac magnetic resonance images of control (Ctrl), PKP2 homozygous mutant (Hom) treated with AAV9 GFP, and PKP2 Hom treated with AAV9 PKP2 hearts. FIG. 4B shows quantification of heart rate, as well as ejection fraction (EF), end-diastolic volumes (EDV), and end-systolic volumes (ESV) in left ventricles (LV) and right ventricles (RV). Mean values with standard deviation. n=5 Ctrl, n=5 Hom-AAV9 GFP, n=6 Hom-AAV9 PKP2. Two-way ANOVA with Tukey post hoc test. \*\*\*\*, p<0.0001. \*\*, p<0.01. \*, p<0.05. FIG. 4C shows a representative composite surface electrocardiograms of control (Ctrl), PKP2 homozygous mutant (Hom) treated with AAV9 GFP, and PKP2 Hom treated with AAV9 PKP2 hearts. Scale bar =20ms. FIG. 4D shows a quantification of heart rate, PR interval, and QRS interval. Mean values with standard deviation. n=5 Ctrl, n=5 Hom-AAV9 GFP, n=4 Hom-AAV9 PKP2. One-way ANOVA with Tukey post hoc test. \*, p<0.05. FIG. 4E shows a representative surface electrocardiograms depicting electrical activity through time. Premature ventricular contractions (PVCs) are depicted with arrows. Quantification of percentage mice with PVCs for each condition.

[0033] FIGS. 5A-5C show early AAV9 PKP2 administration preserves cardiac morphology and prevents pathogenic tissue remodeling. FIG. 5A shows a representative cardiac histological sections with hematoxylin & eosin stain from control (Ctrl), PKP2 homozygous mutant (Hom) treated with AAV9 GFP, and PKP2 Hom treated with AAV9 PKP2 hearts. Scale bar =1mm. FIG. 5B shows a representative cardiac histological sections with Masson's trichrome stain for fibrosis from Ctrl, Hom-AAV9 GFP, and Hom-AAV9 PKP2 within left ventricles (LV) and right ventricles (RV). Scale bar =100µM. FIG. 5C shows a reverse transcription-quantitative PCR analysis of pro-fibrotic gene collagen type I alpha 1 (Coll1a1) with RNA from Ctrl, Hom-AAV9 GFP, and Hom-AAV9 PKP2 hearts.

Mean values with standard deviation. n=4 Ctrl, n=4 Hom-AAV9 GFP, n=6 Hom-AAV9 PKP2. One-way ANOVA with Tukey post hoc test. \*, p<0.05.

**[0034]** FIGS. 6A-6G shows early AAV9 PKP2 administration improves survival and provides durable cardiac protection. FIG. 6A shows survival analysis of Ctrl, PKP2 homozygous mutant (Hom), and PKP2 Hom-AAV9 PKP2 mice. FIG. 6B shows a representative short-axis cardiac magnetic resonance images of Ctrl and PKP2 Hom-AAV9 PKP2 hearts at 6 months of age. FIG. 6C shows an ejection fraction (EF) quantification of left ventricles (LV) and right ventricles (RV) at 6 months of age. Mean values with standard deviation. n=2 Ctrl, n=4 Hom-AAV9 PKP2. Two-way ANOVA with Tukey post hoc test. FIG. 6D shows a representative composite surface electrocardiograms of Ctrl and PKP2 Hom-AAV9 PKP2 hearts at 6 months of age. Scale bar =10ms. FIG. 6E shows a quantification of heart rate, PR interval, and QRS interval. Mean values with standard deviation. n=2 Ctrl, n=4 Hom-AAV9 PKP2. Unpaired t-test. FIG. 6F shows a western blot analysis of Ctrl and PKP2 Hom-AAV9 PKP2 hearts for desmosomal proteins (PKP2, DSP, DSG2, JUP), fascia-adherens protein (N-CAD), and gap junction protein (CX43). GAPDH serves as the loading control. FIG. 6G shows blood serum analysis for alkaline phosphatase (ALP) and alanine aminotransferase (ALT) liver enzyme levels. Mean values with standard deviation. n=5 Ctrl, n=6 Hom-AAV9 PKP2. Unpaired t-test.

**[0035]** FIGS. 7A-7D shows late-stage AAV9 PKP2 administration improves cell-cell junction protein levels and mechanical function. FIG. 7A shows a schematic for retro-orbital injection of AAV9 PKP2 at 4 weeks (disease features present) in PKP2 homozygous mutant (PKP2 Hom) mice and analysis of hearts 2 weeks later. FIG. 7B shows a western blot analysis of Ctrl, PKP2 Hom-AAV9 GFP, and PKP2 Hom-AAV9 PKP2 hearts for desmosomal proteins (PKP2, DSP, DSG2, JUP), fascia-adherens protein (N-CAD), and gap junction protein (CX43). GAPDH serves as the loading control. FIG. 7C shows representative short-axis cardiac magnetic resonance images of PKP2 Hom-AAV9 GFP and PKP2 Hom-AAV9 PKP2 hearts at both end-diastole and end-systole at two weeks post-injection. FIG. 7D shows an ejection fraction (EF) quantification of left ventricles (LV) and right ventricles (RV) two weeks post-injection. Mean values with standard deviation. n=6 Hom-AAV9 GFP, n=6 Hom-AAV9 PKP2. Two-way ANOVA with Tukey post hoc test. \*\*, p<0.01. \*, p<0.05. FIG. 7E shows survival analysis of Ctrl, PKP2 Hom-AAV9 GFP, and PKP2 Hom-AAV9 PKP2 mice. Log-rank test. \*\*\*, p<0.001.



[0036] FIGS. 8A-8E shows Adeno(-associated) virus technology can stably express human PKP2 protein in adult mouse heart and circumvent ARVC disease outcomes in PKP2 Hom mice.

[0037] FIG. 8A is a western blot analysis of AAV9-hPKP2 or AAVrh10-PKP2 delivered to the hearts of adult wild-type control mice. Study 1 with AAV9-hPKP2 had a duration of 10 days before expression in the heart of the mice was evaluated. Study 2 with AAVrh10-hPKP2 had a duration of 21 days before expression in the heart and liver of the mice was evaluated. PKP2 and DSP expression was evaluated with beta-actin and GAPDH serving as loading controls.

10 [0038] Fig. 8B depicts four week survival curve subsequent early administration (postnatal day 2 (P2)) of formula and hPKP2 (via AAV9 and AAVrh10) in PKP2 Hom mice.

[0039] Fig. 8C shows bar graph analyses of ectopic beats/premature ventricular contractions (PVC) in PKP2 Hom mice following surface ECG analysis and early administration (P2) of formula and hPKP2 (via AAV9 and AAVrh10).

15 [0040] Fig. 8D shows representative cardiac short axis views of magnetic resonance images at end-diastole from wild type control untreated mice, PKP2 Hom treated with formula, PKP2 Hom treated AAV9-hPKP2 and PKP2 Hom treated AAVrh10-hPKP2. Right ventricle (RV) and left ventricle (LV) dimensions are outlined in each group at end-diastol.

[0041] Fig. 8E shows western blot analysis of PKP2 and cell-cell junction proteins (desmoplakin (DSP), desmoglein-2 (DSG2), connexin43 (Cx43), N-cadherin (NCAD), plakoglobin (JUP) in hearts from wild type control untreated mice, PKP2 Hom treated with formula, PKP2 Hom treated AAV9-hPKP2 and PKP2 Hom treated AAVrh10-hPKP2..

20

#### **DETAILED DESCRIPTION**

25 [0042] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

[0043] Unless defined otherwise, all technical and scientific terms and any acronyms used herein have the same meanings as commonly understood by one of ordinary skill in the art in the field of the invention. Although any methods and materials similar or equivalent to those described herein can be used in the practice of the present invention, the exemplary methods, devices, and materials are described herein.

30

[0044] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as, Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed. (Sambrook et al., 1989); Oligonucleotide Synthesis (M. J. Gait, ed., 1984); Animal Cell Culture (R. I. Freshney, ed., 1987); Methods in Enzymology (Academic Press, Inc.); Current Protocols in Molecular Biology (F. M. Ausubel et al., eds., 1987, and periodic updates); PCR: The Polymerase Chain Reaction (Mullis et al., eds., 1994); Remington, The Science and Practice of Pharmacy, 20<sup>th</sup> ed., (Lippincott, Williams & Wilkins 2003), and Remington, The Science and Practice of Pharmacy, 22<sup>th</sup> ed., (Pharmaceutical Press and Philadelphia College of Pharmacy at University of the Sciences 2012).

[0045] The invention provides compositions and methods for preventing and treating cardiac arrhythmia. In some aspects, the invention provides a method of preventing or treating arrhythmogenic right ventricular cardiomyopathy (ARVC), comprising administering to a subject in need a prophylactic or treatment effective amount of a composition comprising a plakophilin-2 (PKP2) gene.

[0046] In some aspects, the invention provides that the composition further comprises an adenovirus-associated vector (AAV) to deliver the PKP2 gene. In some aspects, the invention provides that the AAV is a cardiotropic AAV serotype and contains a cardiac-specific promoter.

[0047] The present disclosure provides, *inter alia*, isolated polynucleotides, recombinant adeno-associated virus (rAAV) vectors, and rAAV viral vectors comprising transgene nucleic acid molecules comprising nucleic acid sequences encoding for plakophilin-2 (PKP2) polypeptides. The present disclosure also provides methods of manufacturing these isolated polynucleotides, rAAV vectors, and rAAV viral vectors, as well as their use to deliver transgenes to treat or prevent a disease or disorder, including diseases associated with loss and/or malfunction of an PKP2 gene.

[0048] The disclosure provides rAAV vectors or rAAV viral vectors comprising a nucleic acid sequence encoding plakophilin-2 (PKP2) to scaffold and reassemble the cardiac cell-cell junction complex and alleviate both the electrical and structural abnormalities in ARVC. No published studies have shown the sufficiency of a single gene (desmosomal or otherwise) to reassemble the cardiac cell-cell junction complex and prevent

ARVC disease development. Among many things, the disclosure demonstrates that AAV-mediated delivery of PKP2 in neonatal cardiomyocytes harboring a prevalent human PKP2 mutation can rescue the loss of cardiac cell-cell junction proteins driving cardiac electrical and structural abnormalities in this model. Further, the disclosure shows that AAV-mediated delivery of PKP2 in PKP2 mutant neonatal cardiomyocytes harboring this prevalent human PKP2 mutation can similarly rescue the loss of cardiac cell-cell junction proteins, suggesting that loss of PKP2 protein dosage is a key driver of cardiac structural and electrical deficits in this model. The disclosure further demonstrates that early stage administration of AAV-mediated PKP2 gene therapy in neonatal mice harboring this prevalent human PKP2 mutation was sufficient to prevent the postnatal breakdown of the cardiac cell-cell junction complex and prevent adult ARVC disease development (preservation of cardiac electrical and mechanical function) as well as significantly improve lifespan of mice. The disclosure further shows that late stage administration of adeno-associated-viral-mediated PKP2 gene therapy in adult mice harboring this prevalent human PKP2 mutation was sufficient to rescue and reassemble cell-cell junction proteins and improve cardiac function as well as prevent mortality. This data altogether highlight that PKP2 functions as an efficient molecular scaffold capable of reassembling the cardiac cell-cell junction and PKP2 gene therapy can serve as a valuable therapeutic option for ARVC patients when administered prophylactically or late in disease progression.

[0049] The term "adeno-associated virus" or "AAV" as used herein refers to a member of the class of viruses associated with this name and belonging to the genus Dependoparvovirus, family Parvoviridae. Adeno-associated virus is a single-stranded DNA virus that grows in cells in which certain functions are provided by a co-infecting helper virus. General information and reviews of AAV can be found in, for example, Carter, 1989, Handbook of Parvoviruses, Vol. 1, pp. 169- 228, and Berns, 1990, Virology, pp. 1743-1764, Raven Press, (New York). It is fully expected that the same principles described in these reviews will be applicable to additional AAV serotypes characterized after the publication dates of the reviews because it is well known that the various serotypes are quite closely related, both structurally and functionally, even at the genetic level. (See, for example, Blacklowe, 1988, pp. 165-174 of Parvoviruses and Human Disease, J. R. Pattison, ed.; and Rose, Comprehensive Virology 3: 1-61 (1974)). For example, all AAV serotypes apparently exhibit very similar replication properties mediated by homologous rep genes; and all bear three related capsid proteins such as those expressed in AAV2. The degree of relatedness is

further suggested by heteroduplex analysis which reveals extensive cross-hybridization between serotypes along the length of the genome; and the presence of analogous self-annealing segments at the termini that correspond to "inverted terminal repeat sequences" (ITRs). The similar infectivity patterns also suggest that the replication functions in each serotype are under similar regulatory control. Multiple serotypes of this virus are known to be suitable for gene delivery; all known serotypes can infect cells from various tissue types. At least 11 sequentially numbered AAV serotypes are known in the art. Non-limiting exemplary serotypes useful in the methods disclosed herein include any of the 11 serotypes, e.g., AAV2, AAV8, AAV9, or variant serotypes, e.g., AAV-DJ and AAV PHP.B. The AAV particle comprises, consists essentially of, or consists of three major viral proteins: VP1, VP2 and VP3. In some aspects, the AAV refers to the serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVPHP.B, AAVrh74 or AAVrh10.

**[0050]** Exemplary adeno-associated viruses and recombinant adeno-associated viruses include, but are not limited to all serotypes (e.g., AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVPHP.B, AAVrh74 and AAVrh10). Exemplary adeno-associated viruses and recombinant adeno-associated viruses include, but are not limited to, self-complementary AAV (scAAV) and AAV hybrids containing the genome of one serotype and the capsid of another serotype (e.g., AAV2/5, AAV-DJ and AAV-DJ8). Exemplary adeno-associated viruses and recombinant adeno-associated viruses include, but are not limited to, rAAV-LK03, AAV-KP-1 (described in detail in Kerun *et al.* JCI Insight, 2019; 4(22):e131610) and AAV-NP59 (described in detail in Paulk *et al.* Molecular Therapy, 2018; 26(1): 289-303).

#### AAV Structure and Function

**[0051]** AAV is a replication-deficient parvovirus, the single-stranded DNA genome of which is about 4.7 kb in length, including two 145-nucleotide inverted terminal repeat (ITRs). There are multiple serotypes of AAV. The nucleotide sequences of the genomes of the AAV serotypes are known. For example, the complete genome of AAV-1 is provided in GenBank Accession No. NC\_002077; the complete genome of AAV-2 is provided in GenBank Accession No. NC\_001401 and Srivastava *et al.*, J. Virol., 45: 555-564 (1983); the complete genome of AAV-3 is provided in GenBank Accession No. NC\_1829; the complete genome of AAV-4 is provided in GenBank Accession No. NC\_001829; the AAV-5 genome is provided in GenBank Accession No. AF085716; the complete genome of AAV-

6 is provided in GenBank Accession No. NC\_001862; at least portions of AAV-7 and AAV-8 genomes are provided in GenBank Accession Nos. AX753246 and AX753249, respectively; the AAV-9 genome is provided in Gao et al., *J. Virol.*, 78: 6381-6388 (2004); the AAV-10 genome is provided in *Mol. Ther.*, 13(1): 67-76 (2006); and the AAV-11 genome is provided in *Virology*, 330(2): 375-383 (2004). The sequence of the AAV rh.74 genome is provided in U.S. Patent 9,434,928. U.S. Patent No. 9,434,928 also provides the sequences of the capsid proteins and a self-complementary genome. In one aspect, an AAV genome is a self-complementary genome. Cis-acting sequences directing viral DNA replication (rep), encapsidation/packaging, and host cell chromosome integration are contained within AAV ITRs. Three AAV promoters (named p5, p19, and p40 for their relative map locations) drive the expression of the two AAV internal open reading frames encoding rep and cap genes. The two rep promoters (p5 and p19), coupled with the differential splicing of the single AAV intron (at nucleotides 2107 and 2227), result in the production of four rep proteins (rep 78, rep 68, rep 52, and rep 40) from the rep gene. Rep proteins possess multiple enzymatic properties that are ultimately responsible for replicating the viral genome.

[0052] The cap gene is expressed from the p40 promoter and encodes the three capsid proteins, VP1, VP2, and VP3. Alternative splicing and non-consensus translational start sites are responsible for the production of the three related capsid proteins. More specifically, after the single mRNA from which each of the VP1, VP2 and VP3 proteins are translated is transcribed, it can be spliced in two different manners: either a longer or shorter intron can be excised, resulting in the formation of two pools of mRNAs: a 2.3 kb- and a 2.6 kb-long mRNA pool. The longer intron is often preferred and thus the 2.3-kb-long mRNA can be called the major splice variant. This form lacks the first AUG codon, from which the synthesis of VP1 protein starts, resulting in a reduced overall level of VP1 protein synthesis. The first AUG codon that remains in the major splice variant is the initiation codon for the VP3 protein. However, upstream of that codon in the same open reading frame lies an ACG sequence (encoding threonine) which is surrounded by an optimal Kozak (translation initiation) sequence. In some aspects, the Kozak sequence is set forth in SEQ ID NO: 3. This contributes to a low level of synthesis of the VP2 protein, which is actually the VP3 protein with additional N terminal residues, as is VP1, as described in Becerra SP et al., (December 1985). "Direct mapping of adeno-associated virus capsid proteins B and C: a possible ACG initiation codon". *Proceedings of the National Academy of Sciences of*

the United States of America. 82 (23): 7919–23, Cassinotti P et al., (November 1988). "Organization of the adeno-associated virus (AAV) capsid gene: mapping of a minor spliced mRNA coding for virus capsid protein 1". *Virology*. 167 (1): 176–84, Muralidhar S et al., (January 1994). "Site-directed mutagenesis of adeno-associated virus type 2 structural protein initiation codons: effects on regulation of synthesis and biological activity". *Journal of Virology*. 68 (1): 170–6, and Trempe JP, Carter BJ (September 1988). "Alternate mRNA splicing is required for synthesis of adeno-associated virus VP1 capsid protein". *Journal of Virology*. 62 (9): 3356–63, each of which is herein incorporated by reference. A single consensus polyA site is located at map position 95 of the AAV genome. The life cycle and genetics of AAV are reviewed in Muzyczka, *Current Topics in Microbiology and Immunology*, 158: 97-129 (1992).

**[0053]** Each VP1 protein contains a VP1 portion, a VP2 portion and a VP3 portion. The VP1 portion is the N-terminal portion of the VP1 protein that is unique to the VP1 protein. The VP2 portion is the amino acid sequence present within the VP1 protein that is also found in the N-terminal portion of the VP2 protein. The VP3 portion and the VP3 protein have the same sequence. The VP3 portion is the C-terminal portion of the VP1 protein that is shared with the VP1 and VP2 proteins.

**[0054]** The VP3 protein can be further divided into discrete variable surface regions I-IX (VR-I-IX). Each of the variable surface regions (VRs) can comprise or contain specific amino acid sequences that either alone or in combination with the specific amino acid sequences of each of the other VRs can confer unique infection phenotypes (e.g., decreased antigenicity, improved transduction and/or tissue-specific tropism relative to other AAV serotypes) to a particular serotype as described in DiMatta et al., "Structural Insight into the Unique Properties of Adeno-Associated Virus Serotype 9" *J. Virol.*, Vol. 86 (12): 6947-6958, June 2012, the contents of which are incorporated herein by reference.

**[0055]** AAV possesses unique features that make it attractive as a vector for delivering foreign DNA to cells, for example, in gene therapy. AAV infection of cells in culture is noncytopathic, and natural infection of humans and other animals is silent and asymptomatic. Moreover, AAV infects many mammalian cells allowing the possibility of targeting many different tissues in vivo. Moreover, AAV transduces slowly dividing and non-dividing cells, and can persist essentially for the lifetime of those cells as a transcriptionally active nuclear episome (extrachromosomal element). The AAV proviral genome is inserted as cloned DNA in plasmids, which makes construction of recombinant

genomes feasible. Furthermore, because the signals directing AAV replication and genome encapsidation are contained within the ITRs of the AAV genome, some or all of the internal approximately 4.3 kb of the genome (encoding replication and structural capsid proteins, rep-cap) may be replaced with foreign DNA to generate AAV vectors. The rep and cap proteins may be provided in trans. Another significant feature of AAV is that it is an extremely stable and hearty virus. It easily withstands the conditions used to inactivate adenovirus (56° to 65°C for several hours), making cold preservation of AAV less critical. AAV may even be lyophilized. Finally, AAV-infected cells are not resistant to superinfection.

10 [0056] Multiple studies have demonstrated long-term (> 1.5 years) recombinant AAV-mediated protein expression in muscle. See, Clark et al., *Hum Gene Ther*, 8: 659-669 (1997); Kessler et al., *Proc Nat. Acad Sc. USA*, 93: 14082-14087 (1996); and Xiao et al., *J Virol*, 70: 8098-8108 (1996). See also, Chao et al., *Mol Ther*, 2:619-623 (2000) and Chao et al., *Mol Ther*, 4:217-222 (2001). Moreover, because muscle is highly vascularized, recombinant AAV transduction has resulted in the appearance of transgene products in the systemic circulation following intramuscular injection as described in Herzog et al., *Proc Natl Acad Sci USA*, 94: 5804-5809 (1997) and Murphy et al., *Proc Natl Acad Sci USA*, 94: 13921- 13926 (1997). Moreover, Lewis et al., *J Virol*, 76: 8769-8775 (2002) demonstrated that skeletal myofibers possess the necessary cellular factors for correct antibody glycosylation, folding, and secretion, indicating that muscle is capable of stable expression of secreted protein therapeutics. Recombinant AAV (rAAV) genomes of the invention comprise, consist essentially of, or consist of a nucleic acid molecule encoding a therapeutic protein (e.g., PKP2) and one or more AAV ITRs flanking the nucleic acid molecule. Production of pseudotyped rAAV is disclosed in, for example, WO2001083692. Other types of rAAV variants, for example rAAV with capsid mutations, are also contemplated. See, e.g., Marsic et al., *Molecular Therapy*, 22(11): 1900-1909 (2014). The nucleotide sequences of the genomes of various AAV serotypes are known in the art.

#### Isolated polynucleotides comprising transgene sequences

30 [0057] The present disclosure provides isolated polynucleotides comprising at least one transgene nucleic acid molecule.

[0058] In some aspects, a transgene nucleic acid molecule can comprise a nucleic acid sequence encoding a PKP2 polypeptide, or at least one fragment thereof. As would be appreciated by the skilled artisan, PKP2 is encoded for by the PKP2 gene in the human

genome. Thus, a transgene nucleic acid molecule can comprise, consist essentially of, or consist of an PKP2 sequence, or any fragment thereof. In some aspects, a transgene nucleic acid molecule can comprise a nucleic acid sequence encoding a biological equivalent of a PKP2 polypeptide. In some aspects, the PKP2 polypeptide can be any isoform of PKP2  
5 known in the art. In some aspects, the PKP2 isoform can be the PKP2 2a isoform. In some aspects, the PKP2 isoform can be the PKP2 2b isoform.

**[0059]** As used herein, and unless otherwise specified, a plakophilin-2 (PKP2) gene as described herein means a nucleic acid sequence encoding a functional PKP2 protein. The gene or the encoded protein, may be naturally occurring or modified but retaining its  
10 therapeutic activity as described herein. The gene or the encoded protein can have a nucleotide sequence or an amino acid sequence of an isolated naturally occurring PKP2 gene or protein in a mammal, including of human origin, such as are well known in the published literature.

**[0060]** The term “PKP2” refers to the plakophilin-2 full length protein, and functional  
15 fragments thereof, including amino acid sequences comprising a segment of at least 75%, more preferably at least 80%, 90%, 95%, and most preferably 99% of the full length domain with 100% sequence identity and variations thereof. Variations in the amino acid sequences are contemplated as being encompassed by the present disclosure, providing that the variations in the amino acid sequence maintain at least 75%, more preferably at least 80%,  
20 90%, 95%, and most preferably 99%. Certain percentages in between are included, such as 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99% sequence identity. In particular, conservative amino acid replacements are contemplated. Conservative replacements are those that take place within a family of amino acids that are related in their side chains.  
25 Genetically encoded amino acids are generally divided into families: (1) acidic amino acids are aspartate, glutamate; (2) basic amino acids are lysine, arginine, histidine; (3) non-polar amino acids are alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan, and (4) uncharged polar amino acids are glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. The hydrophilic amino acids include arginine, asparagine, aspartate, glutamine, glutamate, histidine, lysine, serine, and threonine.  
30 The hydrophobic amino acids include alanine, cysteine, isoleucine, leucine, methionine, phenylalanine, proline, tryptophan, tyrosine and valine. Other families of amino acids include (i) serine and threonine, which are the aliphatic-hydroxy family; (ii) asparagine and



glutamine, which are the amide containing family; (iii) alanine, valine, leucine and isoleucine, which are the aliphatic family; and (iv) phenylalanine, tryptophan, and tyrosine, which are the aromatic family. For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid will not have a major effect on the binding or properties of the resulting molecule, especially if the replacement does not involve an amino acid within a framework site. Whether an amino acid change results in a functional PKP2 protein can readily be determined by assaying the specific activity of the protein derivative. Fragments or analogs of PKP2 proteins can be readily prepared by those of ordinary skill in the art. Preferred amino- and carboxy-termini of fragments or analogs occur near boundaries of functional domains. The sequence may be modified for improved therapeutic activity.

**[0061]** The term “PKP2 gene” refers to a plakophilin-2 protein encoding full length nucleotide sequence, DNA or RNA, or a functional fragment thereof, including nucleotide sequences comprising a segment of at least 75%, more preferably at least 80%, 90%, 95%, and most preferably 99% of the full length nucleotide sequence with 100% sequence identity and variations thereof. Fragments include nucleic acid sequences, DNA or RNA, comprising a segment of at least 75%, more preferably at least 80%, 90%, 95%, and most preferably 99% of the full length gene with 100% sequence identity and variations thereof. Variations in the sequences of genes are contemplated as being encompassed by the present disclosure, providing that the variations in the nucleic acid sequence maintain at least 75%, or at least 80%, 90%, 95%, or 99% identity. Certain percentages in between are included, such as 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, and 99% sequence identity. The sequence may be modified for improved therapeutic activity and optimized for delivery, such as with an adeno-associated virus (AAV) or other well-known gene delivery vector system.

**[0062]** In some aspects, a PKP2 polypeptide comprises, consists essentially of, or consists of an amino acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to the amino acid sequence put forth in SEQ ID NO: 1 or SEQ ID NO: 13, or a fragment thereof. In some aspects, a PKP2 polypeptide comprises, consists essentially of, or consists of an amino acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage

in between) identical to at least one portion of the amino acid sequence put forth in SEQ ID NO: 1 or SEQ ID NO: 13, or a fragment thereof.

**[0063]** In some aspects, a PKP2 polypeptide comprises, consists essentially of, or consists of an amino acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to the amino acid sequence put forth in SEQ ID NO: 1, or a fragment thereof. In some aspects, a PKP2 polypeptide comprises, consists essentially of, or consists of an amino acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to at least one portion of the amino acid sequence put forth in SEQ ID NO: 1, or a fragment thereof.

**[0064]** In some aspects, a PKP2 polypeptide comprises, consists essentially of, or consists of an amino acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to the amino acid sequence put forth in SEQ ID NO: 13, or a fragment thereof. In some aspects, a PKP2 polypeptide comprises, consists essentially of, or consists of an amino acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to at least one portion of the amino acid sequence put forth in SEQ ID NO: 13, or a fragment thereof.

**[0065]** In some aspects, a nucleic acid sequence encoding a PKP2 polypeptide comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to any one of the nucleic acid sequences put forth in SEQ ID NO: 4 or SEQ ID NO: 14. In some aspects, a nucleic acid sequence encoding a PKP2 polypeptide comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to the nucleic acid sequence put forth in SEQ ID NO: 4 or SEQ ID NO: 14. A nucleic acid sequence encoding a PKP2 polypeptide can be referred to as a PKP2 sequence.

**[0066]** In some aspects, a nucleic acid sequence encoding a PKP2 polypeptide comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to any one of the nucleic acid sequences put forth in SEQ ID NO: 4. In some aspects, a nucleic acid sequence encoding a PKP2 polypeptide comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%,

97%, 98%, 99% or 100% (or any percentage in between) identical to the nucleic acid sequence put forth in SEQ ID NO: 4.

[0067] In some aspects, a nucleic acid sequence encoding a PKP2 polypeptide comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to any one of the nucleic acid sequences put forth in SEQ ID NO: 14. In some aspects, a nucleic acid sequence encoding a PKP2 polypeptide comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to the nucleic acid sequence put forth in SEQ ID NO: 14.

#### Codon Optimization

[0068] In some aspects, the nucleic acid sequence encoding a PKP2 polypeptide can be a codon optimized nucleic acid sequence that encodes for a PKP2 polypeptide. A codon optimized nucleic acid sequence encoding a PKP2 polypeptide can comprise, consist essentially of, or consist of a nucleic acid sequence that is no more than 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% (or any percentage in between) identical to the wildtype human nucleic acid sequence encoding the PKP2 polypeptide.

[0069] In some aspects, a codon optimized nucleic acid sequence encoding a PKP2 polypeptide can comprise no donor splice sites. In some aspects, a codon optimized nucleic acid sequence encoding a PKP2 polypeptide can comprise no more than about one, or about two, or about three, or about four, or about five, or about six, or about seven, or about eight, or about nine, or about ten donor splice sites. In some aspects, a codon optimized nucleic acid sequence encoding a PKP2 polypeptide comprises at least one, or at least two, or at least three, or at least four, or at least five, or at least six, or at least seven, or at least eight, or at least nine, or at least ten fewer donor splice sites as compared to the wildtype human nucleic acid sequence encoding the PKP2 polypeptide. Without wishing to be bound by theory, the removal of donor splice sites in the codon optimized nucleic acid sequence can unexpectedly and unpredictably increase expression of the PKP2 polypeptide *in vivo*, as cryptic splicing is prevented. Moreover, cryptic splicing may vary between different subjects, meaning that the expression level of the PKP2 polypeptide comprising donor splice sites may unpredictably vary between different subjects. Such unpredictability is unacceptable in the context of human therapy.

[0070] In some aspects, a codon optimized nucleic acid sequence encoding a PKP2 polypeptide can have a GC content that differs from the GC content of the wildtype human nucleic acid sequence encoding the PKP2 polypeptide. In some aspects, the GC content of a codon optimized nucleic acid sequence encoding a PKP2 polypeptide is more evenly distributed across the entire nucleic acid sequence, as compared to the wildtype human nucleic acid sequence encoding the PKP2 polypeptide. Without wishing to be bound by theory, by more evenly distributing the GC content across the entire nucleic acid sequence, the codon optimized nucleic acid sequence exhibits a more uniform melting temperature (“Tm”) across the length of the transcript. The uniformity of melting temperature results unexpectedly in increased expression of the codon optimized nucleic acid in a human subject, as transcription and/or translation of the nucleic acid sequence occurs with less stalling of the polymerase and/or ribosome.

[0071] In some aspects, a codon optimized nucleic acid sequence encoding a PKP2 polypeptide can have fewer repressive microRNA target binding sites as compared to the wildtype human nucleic acid sequence encoding the PKP2 polypeptide. In some aspects, a codon optimized nucleic acid sequence encoding a PKP2 polypeptide can have at least one, or at least two, or at least three, or at least four, or at least five, or at least six, or at least seven, or at least eight, or at least nine, or at least ten, or at least ten fewer repressive microRNA target binding sites as compared to the wildtype human nucleic acid sequence encoding the PKP2 polypeptide. Without wishing to be bound by theory, by having fewer repressive microRNA target binding sites, the codon optimized nucleic acid sequence encoding a PKP2 polypeptide unexpectedly exhibits increased expression in a human subject.

[0072] In some aspects, the codon optimized nucleic acid sequence encoding a PKP2 polypeptide exhibits at least 5%, at least 10%, at least 20%, at least 30%, at least 50%, at least 75%, at least 100%, at least 200%, at least 300%, at least 500%, or at least 1000% increased expression in a human subject relative to a wild-type or non-codon optimized nucleic acid sequence encoding a PKP2 polypeptide.

#### AAV vectors

[0073] In some aspects, the isolated polynucleotides comprising at least one transgene nucleic acid molecule described herein can be a recombinant AAV (rAAV) vector.

[0074] As used herein, the term "vector" refers to a nucleic acid comprising, consisting essentially of, or consisting of an intact replicon such that the vector may be replicated when placed within a cell, for example by a process of transfection, infection, or transformation. It is understood in the art that once inside a cell, a vector may replicate as an extrachromosomal (episomal) element or may be integrated into a host cell chromosome. Vectors may include nucleic acids derived from retroviruses, adenoviruses, herpesvirus, baculoviruses, modified baculoviruses, papovaviruses, or otherwise modified naturally-occurring viruses. Exemplary non-viral vectors for delivering nucleic acid include naked DNA; DNA complexed with cationic lipids, alone or in combination with cationic polymers; anionic and cationic liposomes; DNA-protein complexes and particles comprising, consisting essentially of, or consisting of DNA condensed with cationic polymers such as heterogeneous polylysine, defined-length oligopeptides, and polyethyleneimine, in some cases contained in liposomes; and the use of ternary complexes comprising, consisting essentially of, or consisting of a virus and polylysine-DNA.

[0075] With respect to general recombinant techniques, vectors that contain both a promoter and a cloning site into which a polynucleotide can be operatively linked are well known in the art. Such vectors are capable of transcribing RNA in vitro or in vivo, and are commercially available from sources such as Agilent Technologies (Santa Clara, Calif) and Promega Biotech (Madison, Wis.). In order to optimize expression and/or in vitro transcription, it may be necessary to remove, add or alter 5' and/or 3' untranslated portions of cloned transgenes to eliminate extra, potential inappropriate alternative translation initiation codons or other sequences that may interfere with or reduce expression, either at the level of transcription or translation. Alternatively, consensus ribosome binding sites can be inserted immediately 5' of the start codon to enhance expression.

[0076] An "rAAV vector" as used herein refers to a vector comprising, consisting essentially of, or consisting of one or more transgene sequences and one or more AAV inverted terminal repeat sequences (ITRs). Such AAV vectors can be replicated and packaged into infectious viral particles when present in a host cell that provides the functionality of rep and cap gene products; for example, by transfection of the host cell. In some aspects, AAV vectors contain a promoter, at least one nucleic acid that may encode at least one protein or RNA, and/or an enhancer and/or a terminator within the flanking ITRs that is packaged into the infectious AAV particle. The encapsidated nucleic acid portion may be referred to as the AAV vector genome. Plasmids containing rAAV vectors may also

contain elements for manufacturing purposes, e.g., antibiotic resistance genes, origin of replication sequences etc., but these are not encapsidated and thus do not form part of the AAV particle.

[0077] In some aspects, an rAAV vector can comprise at least one transgene nucleic acid molecule. In some aspects, an rAAV vector can comprise at least one AAV inverted terminal (ITR) sequence. In some aspects, an rAAV vector can comprise at least one promoter sequence. In some aspects, an rAAV vector can comprise at least one enhancer sequence. In some aspects, an rAAV vector can comprise at least one post-transcriptional regulatory element. In some aspects, an rAAV vector can comprise at least one polyA sequence. In some aspects, an rAAV vector can comprise at least one reporter protein. In some aspects, an rAAV vector can comprise a first AAV ITR sequence, a promoter sequence, a transgene nucleic acid molecule, a polyA sequence, and a second AAV ITR sequence. In some aspects, an rAAV vector can comprise, in the 5' to 3' direction, a first AAV ITR sequence, a promoter sequence, a transgene nucleic acid molecule, a polyA sequence, and a second AAV ITR sequence.

[0078] In some aspects, an rAAV vector can comprise a first AAV ITR sequence, a promoter sequence, a transgene nucleic acid molecule, a post-transcriptional regulatory element, a polyA sequence, and a second AAV ITR sequence. In some aspects, an rAAV vector can comprise, in the 5' to 3' direction, a first AAV ITR sequence, a promoter sequence, a transgene nucleic acid molecule, a post-transcriptional regulatory element, a polyA sequence, and a second AAV ITR sequence.

[0079] In some aspects, an rAAV vector can comprise more than one transgene nucleic acid molecule. In some aspects, an rAAV vector can comprise at least two transgene nucleic acid molecules, such that the rAAV vector comprises a first transgene nucleic acid molecule and an at least second transgene nucleic acid molecule. In some aspects, the first and the at least second transgene nucleic acid molecule can comprise the same nucleic acid sequence. In some aspects, the first and the at least second transgene nucleic acid molecules can comprise different nucleic acid sequences. In some aspects, the first and the at least second transgene nucleic acid sequences can be adjacent to each other.

[0080] In some aspects, an rAAV vector can comprise more than one promoter sequence. In some aspects, an rAAV vector can comprise at least two promoter sequences, such that the rAAV vector comprises a first promoter sequence and an at least second promoter sequence. In some aspects, the first and the at least second promoter sequences

can comprise the same sequence. In some aspects, the first and the at least second promoter sequences can comprise different sequences. In some aspects, the first and the at least second promoter sequences can be adjacent to each other. In some aspects wherein an rAAV vector also comprises a first transgene nucleic acid molecule and an at least second transgene nucleic acid molecule, the first promoter can be located upstream (5') of the first transgene nucleic acid molecule and the at least second promoter can be located between the first transgene nucleic acid molecule and the at least second transgene nucleic acid molecule, such that the at least second promoter is downstream (3') of the first transgene nucleic acid molecule and upstream (5') of the at least second transgene nucleic acid molecule.

10 **[0081]** Any of the preceding rAAV vectors can further comprise at least one enhancer. The at least one enhancer can be located anywhere in the rAAV vector. In some aspects, the at least one enhancer can be located immediately upstream (5') of a promoter. Thus, an rAAV vector can comprise, in the 5' to 3' direction, a first AAV ITR sequence, an enhancer, a promoter sequence, a transgene nucleic acid molecule, a poly A sequence, and a second AAV ITR sequence. In some aspects, the at least one enhancer can be located immediately downstream (3') of a promoter. Thus, an rAAV vector can comprise, in the 5' to 3' direction, a first AAV ITR sequence, a promoter sequence, an enhancer, a transgene nucleic acid molecule, a poly A sequence, and a second AAV ITR sequence. In some aspects, the at least one enhancer can be located immediately downstream of a transgene nucleic acid molecule. Thus, an rAAV vector can comprise, in the 5' to 3' direction, a first AAV ITR sequence, a promoter sequence, a transgene nucleic acid molecule, an enhancer, a poly A sequence, and a second AAV ITR sequence.

25 **[0082]** In some aspects, an rAAV vector of the disclosure comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to the nucleic acid sequence put forth in SEQ ID NO: 9, or a fragment thereof.

30 **[0083]** In some aspects, an rAAV vector of the disclosure comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to the nucleic acid sequence put forth in SEQ ID NO: 18, or a fragment thereof.

**[0084]** In some aspects, an rAAV vector of the disclosure comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%,

90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to the nucleic acid sequence put forth in SEQ ID NO: 21, or a fragment thereof.

**[0085]** In some aspects, an rAAV vector of the disclosure comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%,  
5 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to the nucleic acid sequence put forth in SEQ ID NO: 22, or a fragment thereof. f

**[0086]** In some aspects, an rAAV vector of the disclosure comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%,  
10 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to the nucleic acid sequence put forth in SEQ ID NO: 23, or a fragment thereof.

**[0087]** In some aspects, an rAAV vector of the disclosure comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%,  
15 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to the nucleic acid sequence put forth in SEQ ID NO: 24, or a fragment thereof.

In some aspects, an rAAV vector of the disclosure comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%,  
15 97%, 98%, 99% or 100% (or any percentage in between) identical to the nucleic acid sequence put forth in SEQ ID NO: 26, or a fragment thereof.

In some aspects, an rAAV vector of the disclosure comprises, consists essentially of, or  
20 consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to the nucleic acid sequence put forth in SEQ ID NO: 29, or a fragment thereof.

In some aspects, an rAAV vector of the disclosure comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%,  
25 97%, 98%, 99% or 100% (or any percentage in between) identical to the nucleic acid sequence put forth in SEQ ID NO: 30, or a fragment thereof. AAV ITR sequences

**[0088]** In some aspects, an AAV ITR sequence can comprise any AAV ITR sequence known in the art. In some aspects, an AAV ITR sequence can be an AAV1 ITR sequence, an AAV2 ITR sequence, an AAV4 ITR sequence, an AAV5 ITR sequence, an  
30 AAV6 ITR sequence, an AAV7 ITR sequence, an AAV8 ITR sequence, an AAV9 ITR sequence, an AAV10 ITR sequence, an AAV11 ITR sequence, an AAV12 ITR sequence, an AAV13 ITR sequence, an AAVrh74 ITR sequence or an AAVrh10 ITR sequence.



[0089] Thus, in some aspects, an AAV ITR sequence can comprise, consist essentially of, or consist of an AAV1 ITR sequence, an AAV2 ITR sequence, an AAV4 ITR sequence, an AAV5 ITR sequence, an AAV6 ITR sequence, an AAV7 ITR sequence, an AAV8 ITR sequence, an AAV9 ITR sequence, an AAV10 ITR sequence, an AAV11 ITR sequence, an AAV12 ITR sequence, an AAV13 ITR sequence, an AAVrh74 ITR sequence, or an AAVrh10 ITR sequence.

[0090] In some aspects, an rAAV vector of the present disclosure can comprise, consist essentially of, or consist of AAV2 ITR sequences. In some aspects, an rAAV vector of the present disclosure can comprise, consist essentially of, or consist of AAV2 ITR sequences or a modified AAV2 ITR sequence.

[0091] In some aspects, an AAV2 ITR sequence can comprise, consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 7.

[0092] In some aspects, an AAV2 ITR sequence can comprise consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 8.

[0093] In some aspects, an AAV2 ITR sequence can comprise, consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 15.

[0094] In some aspects, an AAV2 ITR sequence can comprise consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 16.

[0095] In some aspects, an AAV2 ITR sequence can comprise, consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 19.

[0096] In some aspects, an AAV2 ITR sequence can comprise consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 20.

[0097] In some aspects, an AAV2 ITR sequence can comprise consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 25.

[0098] In some aspects, a first AAV ITR sequence can comprise consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%,

96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 7 and a second AAV ITR sequence can comprise consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 8.

5 **[0099]** In some aspects, a first AAV ITR sequence can comprise consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 8 and a second AAV ITR sequence can comprise consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or  
10 100% (or any percentage in between) identical to SEQ ID NO: 7.

**[0100]** In some aspects, a first AAV ITR sequence can comprise consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 25 and a second AAV ITR sequence can comprise consist essentially of, or consist of a nucleic  
15 acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 8.

**[0101]** In some aspects, a first AAV ITR sequence can comprise consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 8 and a second AAV ITR sequence can comprise consist essentially of, or consist of a nucleic  
20 acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 25.

**[0102]** In some aspects, a first AAV ITR sequence can comprise consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 15 and a second AAV ITR sequence can comprise consist essentially of, or consist of a nucleic  
25 acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 16.

**[0103]** In some aspects, a first AAV ITR sequence can comprise consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 16 and a second AAV ITR sequence can comprise consist essentially of, or consist of a nucleic  
30

acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 15.

**[0104]** In some aspects, a first AAV ITR sequence can comprise consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%,  
5 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 19 and a second AAV ITR sequence can comprise consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 20.

**[0105]** In some aspects, a first AAV ITR sequence can comprise consist essentially  
10 of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 20 and a second AAV ITR sequence can comprise consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 19.

**[0106]** In some aspects, an ITR sequence of the disclosure can be in any order such  
15 as a forward orientation or flipped in a reverse orientation. In some aspects, an ITR sequence of the disclosure can comprise a mutation, deletion, insertion or re-arrangement of one or more nucleotides in the nucleic acid sequence encoding the ITR sequence.

#### Promoter sequence and enhancers

**[0107]** The term "promoter" and "promoter sequence" as used herein means a  
20 control sequence that is a region of a polynucleotide sequence at which the initiation and rate of transcription of a coding sequence, such as a gene or a transgene, are controlled. Promoters may be constitutive, inducible, repressible, or tissue-specific, for example. Promoters may contain genetic elements at which regulatory proteins and molecules such  
25 as RNA polymerase and transcription factors may bind. Non-limiting exemplary promoters include Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), a cytomegalovirus (CMV) promoter, an SV40 promoter, a dihydrofolate reductase promoter, a  $\beta$ -actin promoter, a phosphoglycerol kinase (PGK) promoter, a U6 promoter, an H1 promoter, a ubiquitous chicken  $\beta$ -actin hybrid (CBh) promoter, a small nuclear RNA (U1a  
30 or U1b) promoter, an MeCP2 promoter, an MeP418 promoter, an MeP426 promoter, a minimal MeCP2 promoter, a VMD2 promoter, an mRho promoter, or an EF1 promoter.

**[0108]** Additional non-limiting exemplary promoters provided herein include, but are not limited to EF1a, Ubc, human  $\beta$ -actin, CAG, TRE, Ac5, Polyhedrin, CaMKIIa, Gal1,

TEF1, GDS, ADH1, Ubi, and  $\alpha$ -1-antitrypsin (hAAT). It is known in the art that the nucleotide sequences of such promoters may be modified in order to increase or decrease the efficiency of mRNA transcription. See, e.g., Gao et al. (2018) Mol. Ther.: Nucleic Acids 12:135-145 (modifying TATA box of 7SK, U6 and H1 promoters to abolish RNA polymerase III transcription and stimulate RNA polymerase II-dependent mRNA transcription). Synthetically-derived promoters may be used for ubiquitous or tissue specific expression. Further, virus-derived promoters, some of which are noted above, may be useful in the methods disclosed herein, e.g., CMV, HIV, adenovirus, and AAV promoters. In some aspects, the promoter is used together with at least one enhancer to increase the transcription efficiency. Non-limiting examples of enhancers include an interstitial retinoid-binding protein (IRBP) enhancer, an RSV enhancer or a CMV enhancer.

**[0109]** In some aspects, a promoter sequence can comprise, consist essentially of, or consist of a Rous sarcoma virus (RSV) LTR promoter sequence (optionally with the RSV enhancer), a cytomegalovirus (CMV) promoter sequence, an SV40 promoter sequence, a dihydrofolate reductase promoter sequence, a  $\beta$ -actin promoter sequence, a phosphoglycerol kinase (PGK) promoter sequence, a U6 promoter sequence, an H1 promoter sequence, a ubiquitous chicken  $\beta$ -actin hybrid (CBh) promoter sequence, a small nuclear RNA (U1a or U1b) promoter sequence, an MeCP2 promoter sequence, an MeP418 promoter sequence, an MeP426 promoter sequence, a minimal MeCP2 promoter sequence, a VMD2 promoter sequence, an mRho promoter sequence, an EFI promoter sequence, an EFla promoter sequence, a Ubc promoter sequence, a human  $\beta$ -actin promoter sequence, a CAG promoter sequence, a TRE promoter sequence, an Ac5 promoter sequence, a Polyhedrin promoter sequence, a CaMKIIa promoter sequence, a Gal1 promoter sequence, a TEF1 promoter sequence, a GDS promoter sequence, an ADH1 promoter sequence, a Ubi promoter sequence or an  $\alpha$ -1-antitrypsin (hAAT) promoter sequence.

**[0110]** In some aspects, a promoter sequence can be a cardiac-specific promoter. In some aspects, the cardiac-specific promoter is a TNNI2 promoter. In some aspects, the cardiac-specific promoter is a NKX2.5 promoter. In some aspects, the cardiac-specific promoter is a cardiac troponin T (cTnT) promoter. In some aspects, the cardiac troponin T promoter drives cardiac-specific expression. In some aspects, the cardiac troponin T promoter drives cardiomyocyte-specific expression.

**[0111]** An enhancer is a regulatory element that increases the expression of a target sequence. A "promoter/enhancer" is a polynucleotide that contains sequences capable of

providing both promoter and enhancer functions. For example, the long terminal repeats of retroviruses contain both promoter and enhancer functions. The enhancer/promoter may be "endogenous" or "exogenous" or "heterologous." An "endogenous" enhancer/promoter is one which is naturally linked with a given gene in the genome. An "exogenous" or  
5 "heterologous" enhancer/promoter is one which is placed in juxtaposition to a gene by means of genetic manipulation (i.e., molecular biological techniques) or synthetic techniques such that transcription of that gene is directed by the linked enhancer/promoter. Non-limiting examples of linked enhancer/promoter for use in the methods, compositions and constructs provided herein include a PDE promoter plus IRBP enhancer or a CMV  
10 enhancer plus U1a promoter. It is understood in the art that enhancers can operate from a distance and irrespective of their orientation relative to the location of an endogenous or heterologous promoter. It is thus further understood that an enhancer operating at a distance from a promoter is thus "operably linked" to that promoter irrespective of its location in the vector or its orientation relative to the location of the promoter.

15 **[0112]** As used throughout the disclosure, the term "operably linked" refers to the expression of a gene (*i.e.* a transgene) that is under the control of a promoter with which it is spatially connected. A promoter can be positioned 5' (upstream) or 3' (downstream) of a gene under its control. A promoter can be positioned 5' (upstream) of a gene under its control. The distance between a promoter and a gene can be approximately the same as the  
20 distance between that promoter and the gene it controls in the gene from which the promoter is derived. Variation in the distance between a promoter and a gene can be accommodated without loss of promoter function.

**[0113]** In some aspects, a promoter sequence can comprise, consist essentially of, or consist of a cardiac troponin T (cTnT) promoter sequence. A cTnT promoter sequence  
25 can comprise, consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 2.

**[0114]** In some aspects, bacterial plasmids of the present disclosure can comprise a prokaryotic promoter.

30 Transgene nucleic acid molecules

**[0115]** In some aspects, a transgene nucleic acid molecule can comprise a nucleic acid sequence encoding a PKP2 polypeptide, or at least one fragment thereof. In some

aspects, a transgene nucleic acid molecule can comprise a nucleic acid sequence encoding a biological equivalent of a PKP2 polypeptide, or at least one fragment thereof.

**[0116]** In some aspects, a PKP2 polypeptide comprises, consists essentially of, or consists of an amino acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 5 97%, 98%, 99% or 100% (or any percentage in between) identical to the amino acid sequence put forth in SEQ ID NO: 1 or SEQ ID NO: 13, or a fragment thereof. In some aspects, a PKP2 polypeptide comprises, consists essentially of, or consists of an amino acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to at least one portion of the amino acid sequence 10 put forth in SEQ ID NO: 1 or SEQ ID NO: 13, or a fragment thereof.

**[0117]** In some aspects, a PKP2 polypeptide comprises, consists essentially of, or consists of an amino acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to the amino acid sequence put forth in SEQ ID NO: 1, or a fragment thereof. In some aspects, a PKP2 15 polypeptide comprises, consists essentially of, or consists of an amino acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to at least one portion of the amino acid sequence put forth in SEQ ID NO: 1, or a fragment thereof.

**[0118]** In some aspects, a PKP2 polypeptide comprises, consists essentially of, or consists of an amino acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to the amino acid sequence put forth in SEQ ID NO: 13, or a fragment thereof. In some aspects, a PKP2 polypeptide comprises, consists essentially of, or consists of an amino acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage 25 in between) identical to at least one portion of the amino acid sequence put forth in SEQ ID NO: 13, or a fragment thereof.

**[0119]** In some aspects, a nucleic acid sequence encoding a PKP2 polypeptide comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) 30 identical to any one of the nucleic acid sequences put forth in SEQ ID NO: 4 or SEQ ID NO: 14. In some aspects, a nucleic acid sequence encoding a PKP2 polypeptide comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical

to the nucleic acid sequence put forth in SEQ ID NO: 4 or SEQ ID NO: 14. A nucleic acid sequence encoding a PKP2 polypeptide can be referred to as a PKP2 sequence.

**[0120]** In some aspects, a nucleic acid sequence encoding a PKP2 polypeptide comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to any one of the nucleic acid sequences put forth in SEQ ID NO: 4. In some aspects, a nucleic acid sequence encoding a PKP2 polypeptide comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to the nucleic acid sequence put forth in SEQ ID NO: 4.

**[0121]** In some aspects, a nucleic acid sequence encoding a PKP2 polypeptide comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to any one of the nucleic acid sequences put forth in SEQ ID NO: 14. In some aspects, a nucleic acid sequence encoding a PKP2 polypeptide comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to the nucleic acid sequence put forth in SEQ ID NO: 14.

**[0122]** In some aspects, a transgene nucleic acid molecule can comprise, consist essentially of, or consist of a nucleic acid sequence encoding a reporter protein. As used herein, a reporter protein is a detectable protein that is operably linked to a promoter to assay the expression (for example, tissue specificity and/or strength) of the promoter. In aspects, a reporter protein may be operably linked to a polypeptide. In aspects, reporter proteins may be used in monitoring DNA delivery methods, functional identification and characterization of promoter and enhancer elements, translation and transcription regulation, mRNA processing and protein: protein interactions. Non-limiting examples of a reporter protein are  $\beta$ -galactosidase; a fluorescent protein, such as, Green Fluorescent Protein (GFP) or Red Fluorescent Protein (RFP); luciferase; glutathione S-transferase; and maltose binding protein.

**[0123]** In some aspects, a transgene nucleic acid molecule can further comprise a nucleic acid sequence encoding a signal peptide.

[0124] In some aspects, a transgene nucleic acid molecule present in an rAAV vector can be under transcriptional control of a promoter sequence also present in the same rAAV vector.

Post-transcriptional regulatory elements

5 [0125] Various post-transcriptional regulatory elements can be used in the viral vectors, for example to increase expression level of the protein of interest in a host cell. In some embodiments, the posttranscriptional regulatory element can be a viral posttranscriptional regulatory element. Non-limiting examples of viral posttranscriptional regulatory element include woodchuck hepatitis virus posttranscriptional regulatory  
10 element (WPRE), hepatitis B virus posttranscriptional regulatory element (HBVPRE), RNA transport element (RTE), and any variants thereof. In some aspects, the post-transcriptional regulatory elements can be an optimized post-transcriptional regulatory elements (oPRE). The oPRE can comprise a nucleic acid sequence that comprises, consists essentially of, or consists of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%,  
15 97%, 98%, 99% or 100% (or any percentage in between) identical to the nucleic acid sequence put forth in SEQ ID NO: 5, SEQ ID NO: 27, or SEQ ID NO: 28.

polyA sequences

[0126] In some aspects, a polyadenylation (polyA) sequence can comprise any polyA sequence known in the art. Non-limiting examples of polyA sequences include, but  
20 are not limited to, an\_MeCP2 polyA sequence, a retinol dehydrogenase 1 (RDH1) polyA sequence, a bovine growth hormone (BGH) polyA sequence, an SV40 polyA sequence, a SPA49 polyA sequence, a sNRP-TK65 polyA sequence, a sNRP polyA sequence, a rabbit beta-globin polyA sequence, or a TK65 polyA sequence.

[0127] Thus, a polyA sequence can comprise, consist essentially of, or consist of an  
25 MeCP2 polyA sequence, a retinol dehydrogenase 1 (RDH1) polyA sequence, a bovine growth hormone (BGH) polyA sequence, an SV40 polyA sequence, a SPA49 polyA sequence, a sNRP-TK65 polyA sequence, a sNRP polyA sequence, or a TK65 polyA sequence.

[0128] In some aspects, a polyA sequence can comprise, consist essentially of, or  
30 consist of a rabbit beta-globin polyA sequence. In some aspects, rabbit beta-globin polyA sequence can comprise, consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to the sequence put forth in SEQ ID NO: 6.



[0129] In some aspects, a polyA sequence can comprise, consist essentially of, or consist of a BGH polyA sequence. In some aspects, BGH polyA sequence can comprise, consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to the sequence put forth in SEQ ID NO: 17.

#### Bacterial Plasmids

[0130] In some aspects, the rAAV vectors of the present disclosure can be contained within a bacterial plasmid to allow for propagation of the rAAV vector *in vitro*. Thus, the present disclosure provides bacterial plasmids comprising any of the rAAV vectors described herein. A bacterial plasmid can further comprise an origin of replication sequence. A bacterial plasmid can further comprise an antibiotic resistance gene. A bacterial plasmid can further comprise a prokaryotic promoter.

[0131] In a non-limiting example, the rAAV vector in the bacterial plasmid comprises, in the 5' to 3' direction, a 5' ITR, a cTnT promoter sequence, a transgene nucleic acid molecule encoding a PKP2 polypeptide, an oPRE sequence, a BGH polyA sequence and a 3' ITR.

[0132] In some aspects, a bacterial plasmid of the present disclosure can comprise, consist essentially of, or consist of the nucleic acid sequence set forth in SEQ ID NO: 10.

#### Origin of replication sequence

[0133] In some aspects, an origin of replication sequence can comprise, consist essentially of, or consist of any origin of replication sequence known in the art. The origin of replication sequence can be a bacterial origin of replication sequence, thereby allowing the rAAV vector comprising said bacterial origin of replication sequence to be produced, propagated and maintained in bacteria, using methods standard in the art.

[0134] In some aspects, an origin of replication sequence can comprise, consist essentially of, or consist of a pUC origin of replication sequence. A pUC19 origin of replication sequence can comprise, consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 11.

#### Antibiotic resistance genes

[0135] In some aspects, rAAV vectors and/or rAAV viral vectors of the disclosure can comprise an antibiotic resistance gene.

[0136] In some aspects, an antibiotic resistance gene can comprise, consist essentially of, or consist of any antibiotic resistance genes known in the art. Examples of antibiotic resistance genes known in the art include, but are not limited to kanamycin resistance genes, spectinomycin resistance genes, streptomycin resistance genes, ampicillin resistance genes, carbenicillin resistance genes, bleomycin resistance genes, erythromycin resistance genes, polymyxin B resistance genes, tetracycline resistance genes and chloramphenicol resistance genes.

[0137] In some aspects, an antibiotic resistance gene can comprise, consist essentially of, or consist of an ampicillin antibiotic resistance gene. An ampicillin antibiotic resistance gene can comprise, consist essentially of, or consist of a nucleic acid sequence at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% (or any percentage in between) identical to SEQ ID NO: 12.

#### AAV viral vectors

[0138] A "viral vector" is defined as a recombinantly produced virus or viral particle that contains a polynucleotide to be delivered into a host cell, either in vivo, ex vivo or in vitro. Examples of viral vectors include retroviral vectors, AAV vectors, lentiviral vectors, adenovirus vectors, alphavirus vectors and the like. Alphavirus vectors, such as Semliki Forest virus-based vectors and Sindbis virus-based vectors, have also been developed for use in gene therapy and immunotherapy. See, e.g., Schlesinger and Dubensky (1999) Curr. Opin. Biotechnol. 5:434-439 and Ying, et al. (1999) Nat. Med. 5(7):823-827.

[0139] An "AAV virion" or "AAV viral particle" or "AAV viral vector" or "rAAV viral vector" or "AAV vector particle" or "AAV particle" refers to a viral particle composed of at least one AAV capsid protein and an encapsidated polynucleotide rAAV vector. Thus, production of an rAAV viral vector necessarily includes production of an rAAV vector, as such a vector is contained within an rAAV vector.

[0140] As used herein, the term "viral capsid" or "capsid" refers to the proteinaceous shell or coat of a viral particle. Capsids function to encapsidate, protect, transport, and release into the host cell a viral genome. Capsids are generally comprised of oligomeric structural subunits of protein ("capsid proteins"). As used herein, the term "encapsidated" means enclosed within a viral capsid. The viral capsid of AAV is composed of a mixture of three viral capsid proteins: VP1, VP2, and VP3. The mixture of VP1, VP2 and VP3 contains 60 monomers that are arranged in a T =1 icosahedral symmetry in a ratio of 1:1:10 (VP1:VP2:VP3) or 1:1:20 (VP1:VP2:VP3) as described in Sonntag F et al., (June 2010). "A

viral assembly factor promotes AAV2 capsid formation in the nucleolus". Proceedings of the National Academy of Sciences of the United States of America. 107 (22): 10220–5, and Rabinowitz JE, Samulski RJ (December 2000). "Building a better vector: the manipulation of AAV virions". Virology. 278 (2): 301–8, each of which is incorporated herein by  
5 reference in its entirety.

**[0141]** The present disclosure provides an rAAV viral vector comprising: a) any of the rAAV vectors described herein; and b) an AAV capsid protein.

**[0142]** An AAV capsid protein can be any AAV capsid protein known in the art. An AAV capsid protein can be an AAV1 capsid protein, an AAV2 capsid protein, an AAV4  
10 capsid protein, an AAV5 capsid protein, an AAV6 capsid protein, an AAV7 capsid protein, an AAV8 capsid protein, an AAV9 capsid protein, an AAV10 capsid protein, an AAV11 capsid protein, an AAV12 capsid protein, an AAV13 capsid protein, an AAVPHP.B capsid protein, an AAVrh74 capsid protein or an AAVrh10 capsid protein. In some aspects, the capsid protein can be an AAV9 capsid protein. In some aspects, the capsid protein can be  
15 an AAVrh10 capsid protein.

#### Compositions and Pharmaceutical Compositions

**[0143]** The present disclosure provides compositions comprising any of the isolated polynucleotides, rAAV vectors, and/or rAAV viral vectors described herein. In some aspects, the compositions can be pharmaceutical compositions. Accordingly, the present  
20 disclosure provides pharmaceutical compositions comprising any of the isolated polynucleotides, rAAV vectors, and/or rAAV viral vectors described herein.

**[0144]** The pharmaceutical composition, as described herein, may be formulated by any methods known or developed in the art of pharmacology, which include but are not limited to contacting the active ingredients (e.g., viral particles or recombinant vectors) with  
25 an excipient and/or additive and/or other accessory ingredient, dividing or packaging the product to a dose unit. The viral particles of this disclosure may be formulated with desirable features, e.g., increased stability, increased cell transfection, sustained or delayed release, biodistributions or tropisms, modulated or enhanced translation of encoded protein in vivo, and the release profile of encoded protein in vivo.

**[0145]** As such, the pharmaceutical composition may further comprise saline,  
30 lipidoids, liposomes, lipid nanoparticles, polymers, lipoplexes, core-shell nanoparticles, peptides, proteins, cells transfected with viral vectors (e.g., for transplantation into a subject), nanoparticle mimics or combinations thereof. In some aspects, the pharmaceutical

composition is formulated as a nanoparticle. In some aspects, the nanoparticle is a self-assembled nucleic acid nanoparticle.

[0146] A pharmaceutical composition in accordance with the present disclosure may be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of  
5 single unit doses. The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage. The formulations of the invention can include one or more excipients and/or additives, each in an amount that together increases the stability of the viral vector, increases cell transfection or transduction  
10 by the viral vector, increases the expression of viral vector encoded protein, and/or alters the release profile of viral vector encoded proteins. In some aspects, the pharmaceutical composition comprises an excipient and/or additive. Non limiting examples of excipients and/or additives include solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or  
15 emulsifying agents, preservatives, or combination thereof.

[0147] In some aspects, the pharmaceutical composition comprises a cryoprotectant. The term "cryoprotectant" refers to an agent capable of reducing or eliminating damage to a substance during freezing. Non-limiting examples of cryoprotectants include sucrose, trehalose, lactose, glycerol, dextrose, raffinose and/or mannitol.

[0148] As used herein the term "pharmaceutically acceptable" means approved by  
20 a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopoeia, other generally recognized pharmacopoeia in addition to other formulations that are safe for use in animals, and more particularly in humans and/or non-human mammals.

[0149] As used herein, the term "pharmaceutically acceptable carrier" encompasses  
25 any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see Martin (1975) Remington's Pharm. Sci., 15th Ed. (Mack Publ. Co., Easton).

[0150] In some aspects, a pharmaceutical composition of the present disclosure can  
30 comprise tris(hydroxymethyl)aminomethane (tris), magnesium chloride, sodium chloride, poloxamer, sucrose or any combination thereof.

[0151] In some aspects, a pharmaceutical composition can comprise sodium chloride, wherein the sodium chloride is present at a concentration of about 100 mM to about 500 mM, or about 200 mM to about 400 mM, or about 300 mM to about 400 mM. In some aspects, the sodium chloride can be present at a concentration of about 200 mM.

5 [0152] In some aspects, a pharmaceutical composition can comprise tris, wherein the tris is present at a concentration of about 10 mM to about 100 mM, or about 10 mM to about 50 mM, or about 15 mM to about 25 mM. In some aspects, the tris can be present at a concentration of about 20 mM.

[0153] In some aspects, a pharmaceutical composition can comprise magnesium chloride, wherein the magnesium chloride is present at a concentration of about 0.1 mM to about 50 mM, or about 0.1 mM to about 5 mM, or about 0.5 mM to about 2.5 mM. In some aspects, the magnesium chloride can be present at a concentration of about 1 mM.

[0154] In some aspects, a pharmaceutical composition can comprise poloxamer 188, wherein the poloxamer 188 is present at a concentration of about 0.001% to about 0.1%, or about 0.005% to about 0.05%. In some aspects, the poloxamer 188 can be present at a concentration of about 0.01%.

[0155] In some aspects, a pharmaceutical composition can comprise sucrose, wherein the sucrose is present at a concentration of about 0.1% to about 10%, or about 0.5% to about 5%. In some aspects, the sucrose can be present at a concentration of about 1%.

20 [0156] In some aspects, a pharmaceutical composition can be formulated at a pH of about 6.5 to about 8.5, or about 7.0 to about 8.0, or about 7.4 to about 7.8. In some aspects, a pharmaceutical composition can be formulated at a pH of about 7.6.

#### Methods of Using the Compositions of the Disclosure

[0157] The present disclosure provides the use of a disclosed composition or pharmaceutical composition for the treatment of a disease or disorder in a cell, tissue, organ, animal, or subject, as known in the art or as described herein, using the disclosed compositions and pharmaceutical compositions, *e.g.*, administering or contacting the cell, tissue, organ, animal, or subject with a therapeutic effective amount of the composition or pharmaceutical composition. In one aspect, the subject is a mammal. Preferably, the subject is human. The terms “subject” and “patient” are used interchangeably herein. For example, the terms “subject” and “patient” can refer to a mammalian subject, including primates (*e.g.*, humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, and the like.

[0158] This disclosure provides methods of preventing or treating a disorder, comprising, consisting essentially of, or consisting of administering to a subject a therapeutically effective amount of any one of the rAAV vectors, rAAV viral vectors, compositions and/or pharmaceutical compositions disclosed herein.

5 [0159] In some aspects, the disclosure provides methods of preventing or treating cardiac arrhythmia. In embodiments, the invention provides a method of preventing or treating arrhythmogenic right ventricular cardiomyopathy (ARVC). In some aspects, the disease can be a genetic disorder involving a PKP2 gene. As would be appreciated by the skilled artisan, ARVC or a PKP2-associated genetic disorders can cause one or more  
10 symptoms in a subject, including, but not limited to, cardiac arrhythmias, fainting, heart palpitations, dizziness, shortness of breath, chest pain, fatigue, persistent cough, premature ventricular contractions, ventricular tachycardia (VT), heart failure, cardiac fibrosis and/or cardiac arrest. In some aspects, ARVC or a PKP2-associated genetic disorder is associated with left ventricular dysfunction and/or fibrofatty replacement of the myocardium leading  
15 to ventricular arrhythmias and sudden cardiac death.

[0160] In some aspects, ARVC is characterized by defects in the cardiac desmosome. As used herein the term “desmosome” refers to cell structures specialized for cell-cell adhesion. Desmosomes are a type of junctional complex that are localized spot-like adhesions randomly arranged on the lateral sides of plasma membranes. Desmosomes found  
20 in cardiac tissue are referred to a cardiac desmosomes.

[0161] In some aspects, a disease can be a disease that is characterized by the loss-of-function of at least one copy of the PKP2 gene in the genome of a subject. In some aspects, a disease can be a disease that is characterized by a decrease in function of at least one copy of the PKP2 gene in the genome of a subject. In some aspects, a disease can be a  
25 disease that is characterized by at least one mutation in at least one mutation in at least one copy of the PKP2 gene in the genome of the subject.

[0162] A mutation in a PKP2 gene can be any type of mutation that is known in the art. Non-limiting examples of mutations include somatic mutations, single nucleotide variants (SNVs), nonsense mutations, insertions, deletions, duplications, frameshift  
30 mutations, repeat expansions, short insertions and deletions (INDELs), long INDELs, alternative splicing, the products of alternative splicing, altered initiation of translation, the products of altered initiation of translation, proteomic cleavage, the products of proteomic cleavage.

[0163] In some aspects, a disease can be a disease that is characterized by a decrease in expression of the PKP2 gene in a subject as compared to a control subject that does not have the disease. In some aspects, the decrease in expression can be at least about 10%, or at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or at least about 95%, or at least about 99%, or at least about 100%.

[0164] In some aspects, a disease can be a disease that is characterized by a decrease in the amount of PKP2 in a subject as compared to a control subject that does not have the disease. In some aspects, the decrease in the amount of PKP2 can be at least about 10%, or at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or at least about 95%, or at least about 99%, or at least about 100%.

[0165] In some aspects, a disease can be a disease that is characterized by a decrease in the activity of PKP2 in a subject as compared to a control subject that does not have the disease. In some aspects, the decrease in the activity of PKP2 can be at least about 10%, or at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90%, or at least about 95%, or at least about 99%, or at least about 100%.

[0166] In some aspects, an rAAV vector or rAAV viral vector comprising a nucleic acid sequencing encoding PKP2 can stabilize the cardiac desmosome in a subject. In some aspects, an rAAV vector or rAAV viral vector comprising a nucleic acid sequencing encoding PKP2 can rescue the loss of cardiac cell-cell junction proteins in a subject. In some aspects, an rAAV vector or rAAV viral vector comprising a nucleic acid sequencing encoding PKP2 can reassemble cell-cell junction proteins in a subject. In some aspects, desmosomal proteins include PKP2, desmoplakin (DSP), Desmoglein-2 (DSG2), plakoglobin (JUP). In some aspects, cell-cell junction proteins include connexin 43 (CX43).

[0167] In some aspects, an rAAV vector or rAAV viral vector comprising a nucleic acid sequencing encoding PKP2 can improve electrical and structural integrity associated with ARVC in a subject. In some aspects, an rAAV vector or rAAV viral vector comprising a nucleic acid sequencing encoding PKP2 can preserve electrical and structural integrity to prevent ARVC in the subject.

[0168] A subject to be treated using the methods, compositions, pharmaceutical compositions, rAAV vectors or rAAV viral vectors of the present disclosure can have any of the diseases and/or symptoms described herein.

[0169] In some aspects, a subject can be less than 0.5 years of age, or less than 1 year of age, or less than 1.5 years of age, or less than 2 years of age, or at less than 2.5 years of age, or less than 3 years of age, or less than 3.5 years of age, or less than 3.5 years of age, or less than 4 years of age, or less than 4.5 years of age, or less than 5 years of age, or less than 5.5 years of age, or less than 6 years of age, or less than 6.5 years of age, or less than 7 years of age, or less than 7.5 years of age, or less than 8 years of age, or less than 8.5 years of age, or less than 9 years of age, or less than 9.5 years of age, or less than 10 years of age. In some aspects the subject can be less than 11 years of age, less than 12 years of age, less than 13 years of age, less than 14 years of age, less than 15 years of age, less than 20 years of age, less than 30 years of age, less than 40 years of age, less than 50 years of age, less than 60 years of age, less than 70 years of age, less than 80 years of age, less than 90 years of age, less than 100 years of age, less than 110 years of age, or less than 120 years of age. In some aspects, a subject can be less than 0.5 years of age. In some aspects, a subject can be less than 4 years of age. In some aspects, a subject can be less than 10 years of age. In some aspects, a subject can be equal to or greater than 18 years of age.

[0170] The methods of treatment and prevention disclosed herein may be combined with appropriate diagnostic techniques to identify and select patients for the therapy or prevention.

[0171] The disclosure provides methods of increasing the level of a protein in a host cell, comprising contacting the host cell with any one of the rAAV viral vectors disclosed herein, wherein the rAAV viral vectors comprises any one of the rAAV vectors disclosed herein, comprising a transgene nucleic acid molecule encoding the protein. In some aspects, the protein is a therapeutic protein. In some aspects, the host cell is *in vitro*, *in vivo*, or *ex vivo*. In some aspects, the host cell is derived from a subject. In some aspects, the subject suffers from a disorder, which results in a reduced level and/or functionality of the protein, as compared to the level and/or functionality of the protein in a normal subject.

[0172] In some aspects, the level of the PKP2 protein is increased to a level equal to or greater than endogenous PKP2 expression. In some aspects, the level of the PKP2 protein is increased at least about 1%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about



45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 100%, at least about 105%, at least about 110%, at least about 120%, at least about 130%, at least about 140%, at least about 150%, at least about 200%, at least about  
5 300%, at least about 400%, or at least about 500% relative to a pre-treatment PKP2 expression level.

**[0173]** The disclosure provides methods of introducing a gene of interest to a cell in a subject comprising contacting the cell with an effective amount of any one of the rAAV viral vectors disclosed herein, wherein the rAAV viral vectors contain any one of the rAAV  
10 vectors disclosed herein, comprising the gene of interest.

**[0174]** In some aspects of the methods of the present disclosure, a subject can also be administered a prophylactic immunosuppressant treatment regimen in addition to being administered an rAAV vector or rAAV viral vector of the present disclosure. In some aspects, an immunosuppressant treatment regimen can comprise administering at least one  
15 immunosuppressive therapeutic. Non limiting examples of immunosuppressive therapeutics include, but are not limited to, Sirolimus (rapamycin), acetaminophen, diphenhydramine, IV methylprednisolone, prednisone, or any combination thereof. An immunosuppressive therapeutic can be administered prior to the day of administration of the rAAV vector and/or rAAV viral vector, on the same day as the administration of the rAAV vector and/or rAAV  
20 viral vector, or any day following the administration of the rAAV vector and/or rAAV viral vector.

**[0175]** A "subject" of diagnosis or treatment is a cell or an animal such as a mammal, or a human. A subject is not limited to a specific species and includes non-human animals subject to diagnosis or treatment and those subject to infections or animal models, including,  
25 without limitation, simian, murine, rat, canine, or leporid species, as well as other livestock, sport animals, or pets. In some aspects, the subject is a human.

**[0176]** As used herein, "treating" or "treatment" of a disease in a subject refers to (1) preventing the symptoms or disease from occurring in a subject that is predisposed or does not yet display symptoms of the disease; (2) inhibiting the disease or arresting its  
30 development; or (3) ameliorating or causing regression of the disease or the symptoms of the disease. As understood in the art, "treatment" is an approach for obtaining beneficial or desired results, including clinical results. For the purposes of the present technology, beneficial or desired results can include one or more, but are not limited to, alleviation or

amelioration of one or more symptoms, diminishment of extent of a condition (including a disease), stabilized (i.e., not worsening) state of a condition (including disease), delay or slowing of condition (including disease), progression, amelioration or palliation of the condition (including disease), states and remission (whether partial or total), whether  
5 detectable or undetectable.

[0177] As used herein, and unless otherwise specified, the terms "prevent," "preventing" and "prevention" refer to the prevention of the onset, recurrence or spread of a disease or disorder, or of one or more symptoms thereof. In certain embodiments, the terms refer to the treatment with or administration of a compound or dosage form provided herein,  
10 with or without one or more other additional active agent(s), prior to the onset of symptoms, particularly to subjects at risk of disease or disorders provided herein. The terms encompass the inhibition or reduction of a symptom of the particular disease. In certain embodiments, subjects with familial history of a disease are potential candidates for preventive regimens. In certain embodiments, subjects who have a history of recurring symptoms are also  
15 potential candidates for prevention. In this regard, the term "prevention" may be interchangeably used with the term "prophylactic treatment."

[0178] As used herein, and unless otherwise specified, a "prophylactically effective amount" of a compound is an amount sufficient to prevent a disease or disorder, or prevent its recurrence. A prophylactically effective amount of a compound means an amount of  
20 therapeutic agent, alone or in combination with one or more other agent(s), which provides a prophylactic benefit in the prevention of the disease. The term "prophylactically effective amount" can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of another prophylactic agent.

[0179] As used herein the term "effective amount" intends to mean a quantity  
25 sufficient to achieve a desired effect. In the context of therapeutic or prophylactic applications, the effective amount will depend on the type and severity of the condition at issue and the characteristics of the individual subject, such as general health, age, sex, body weight, and tolerance to pharmaceutical compositions. In the context of gene therapy, the effective amount can be the amount sufficient to result in regaining part or full function of  
30 a gene that is deficient in a subject. In some aspects, the effective amount of an rAAV viral vector is the amount sufficient to result in expression of a gene in a subject such that PKP2 is produced. In some aspects, the effective amount is the amount required to increase

galactose metabolism in a subject in need thereof. The skilled artisan will be able to determine appropriate amounts depending on these and other factors.

5 [0180] In some aspects, the effective amount will depend on the size and nature of the application in question. It will also depend on the nature and sensitivity of the target subject and the methods in use. The skilled artisan will be able to determine the effective amount based on these and other considerations. The effective amount may comprise, consist essentially of, or consist of one or more administrations of a composition depending on the embodiment.

10 [0181] As used herein, the term "administer" or "administration" intends to mean delivery of a substance to a subject such as an animal or human. Administration can be effected in one dose, continuously or intermittently throughout the course of treatment. Methods of determining the most effective means and dosage of administration are known to those of skill in the art and will vary with the composition used for therapy, the purpose of the therapy, as well as the age, health or gender of the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician or in the case of pets and other animals, treating veterinarian.

15 [0182] Methods of determining the most effective means and dosage of administration are known to those of skill in the art and will vary with the composition used for therapy, the purpose of the therapy and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician. It is noted that dosage may be impacted by the route of administration. Suitable dosage formulations and methods of administering the agents are known in the art. Non-limiting examples of such suitable dosages may be as low as  $10^9$  vector genomes to as much as  $10^{17}$  vector genomes per administration.

20 [0183] In some aspects of the methods described herein, the number of viral particles (e.g., rAAV viral vectors) administered to the subject ranges from about  $10^9$  to about  $10^{17}$ . In some aspects, about  $10^{10}$  to about  $10^{12}$ , about  $10^{11}$  to about  $10^{13}$ , about  $10^{11}$  to about  $10^{12}$ , about  $10^{11}$  to about  $10^{14}$ , about  $10^{12}$  to about  $10^{16}$ , about  $10^{13}$  to about  $10^{16}$ , about  $10^{14}$  to about  $10^{15}$ , about  $5 \times 10^{11}$  to about  $5 \times 10^{12}$ , or about  $10^{12}$  to about  $10^{13}$  viral particles are administered to the subject.

30 [0184] In some aspects of the methods described herein, the number of viral particles (e.g., rAAV viral vectors) administered to the subject is at least about  $10^{10}$ , or at

least about  $10^{11}$ , or at least about  $10^{12}$ , or at least about  $10^{13}$ , or at least about  $10^{14}$ , or at least about  $10^{15}$ , or at least about  $10^{16}$ , or at least about  $10^{17}$  viral particles.

[0185] In some aspects, rAAV vectors, rAAV viral vectors, compositions and/or pharmaceutical compositions disclosed herein are administered to a subject at a dose of ranging from about  $1.0 \times 10^{11}$  vector genomes (vg)/kg to about  $1.0 \times 10^{15}$  vg/kg. In some aspects, the dose is administered at a range of about  $1.0 \times 10^{12}$  vg/kg to about  $1.0 \times 10^{14}$  vg/kg. In some aspects, the dose is administered at a range of about  $1.0 \times 10^{12}$  vg/kg to about  $1.0 \times 10^{13}$  vg/kg. In some aspects, the dose is about  $1.0 \times 10^{12}$  vg/kg, about  $1.5 \times 10^{12}$  vg/kg, about  $2.0 \times 10^{12}$  vg/kg, about  $2.5 \times 10^{12}$  vg/kg, about  $3.0 \times 10^{12}$  vg/kg, about  $4.0 \times 10^{12}$  vg/kg, about  $4.5 \times 10^{12}$  vg/kg, about  $5.0 \times 10^{12}$  vg/kg, about  $5.5 \times 10^{12}$  vg/kg, about  $6.0 \times 10^{12}$  vg/kg, about  $6.5 \times 10^{12}$  vg/kg, about  $7.0 \times 10^{12}$  vg/kg, about  $7.5 \times 10^{12}$  vg/kg, about  $8.0 \times 10^{12}$  vg/kg, about  $8.5 \times 10^{12}$  vg/kg, about  $9.0 \times 10^{12}$  vg/kg, about  $9.5 \times 10^{12}$  vg/kg, about  $1.0 \times 10^{13}$  vg/kg, about  $1.5 \times 10^{13}$  vg/kg, about  $2.0 \times 10^{13}$  vg/kg, about  $2.5 \times 10^{13}$  vg/kg, about  $3.0 \times 10^{13}$  vg/kg, about  $4.0 \times 10^{13}$  vg/kg, about  $4.5 \times 10^{13}$  vg/kg, about  $5.0 \times 10^{13}$  vg/kg, about  $5.5 \times 10^{13}$  vg/kg, about  $6.0 \times 10^{13}$  vg/kg, about  $6.5 \times 10^{13}$  vg/kg, about  $7.0 \times 10^{13}$  vg/kg, about  $7.5 \times 10^{13}$  vg/kg, about  $8.0 \times 10^{13}$  vg/kg, about  $8.5 \times 10^{13}$  vg/kg, about  $9.0 \times 10^{13}$  vg/kg, about  $9.5 \times 10^{13}$  vg/kg, about  $8.0 \times 10^{12}$  vg/kg, about  $8.5 \times 10^{12}$  vg/kg, about  $9.0 \times 10^{12}$  vg/kg, about  $9.5 \times 10^{12}$  vg/kg, about  $1.0 \times 10^{14}$  vg/kg, about  $1.5 \times 10^{14}$  vg/kg, about  $2.0 \times 10^{14}$  vg/kg, about  $2.5 \times 10^{14}$  vg/kg, about  $3.0 \times 10^{14}$  vg/kg, about  $4.0 \times 10^{14}$  vg/kg, about  $4.5 \times 10^{14}$  vg/kg, about  $5.0 \times 10^{14}$  vg/kg, about  $5.5 \times 10^{14}$  vg/kg, about  $6.0 \times 10^{14}$  vg/kg, about  $6.5 \times 10^{14}$  vg/kg, about  $7.0 \times 10^{14}$  vg/kg, about  $7.5 \times 10^{14}$  vg/kg, about  $8.0 \times 10^{14}$  vg/kg, about  $8.5 \times 10^{14}$  vg/kg, about  $9.0 \times 10^{14}$  vg/kg, or about  $9.5 \times 10^{14}$  vg/kg.

[0186] In some aspects, the amounts of viral particles in a composition, pharmaceutical composition, or the amount of viral particles administered to a patient can be calculated based on the percentage of viral particles that are predicted to contain viral genomes.

[0187] In some aspects, rAAV viral vectors of the present disclosure can be introduced to the subject intravenously, intrathecally, intracerebrally, intraventricularly, intranasally, intratracheally, intra-aurally, intra-ocularly, or peri-ocularly, orally, rectally, transmucosally, inhalationally, transdermally, parenterally, subcutaneously, intradermally, intramuscularly, intracisternally, intranervally, intrapleurally, topically, intralymphatically, intracisternally; such introduction may also be intra-arterial, intracardiac, subventricular, epidural, intracerebral, intracerebroventricular, sub-retinal, intravitreal, intraarticular,

intraperitoneal, intrauterine, intranerve or any combination thereof. In some aspects, the viral particles are delivered to a desired target tissue, e.g., to cardiac tissues, as a non-limiting example. In some aspects, delivery of viral particles is systemic. The intracisternal route of administration involves administration of a drug directly into the cerebrospinal fluid of the brain ventricles. It could be performed by direct injection into the cisterna magna or via a permanently positioned tube. In some aspects, the rAAV viral vectors of the present disclosure are administered parenterally. In some aspects, the rAAV viral vectors of the present disclosure are administered via intraperitoneal administration. In some aspects, the rAAV viral vectors of the present disclosure are administered intravenously.

10 **[0188]** In some aspects, the rAAV viral vectors of the present disclosure repair a gene deficiency in a subject. In some aspects, the ratio of repaired target polynucleotide or polypeptide to unrepaired target polynucleotide or polypeptide in a successfully treated cell, tissue, organ or subject is at least about 1.5:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 20:1, about 50:1, about 100:1, about 1000:1, about 10,000:1, about 100,000:1, or about 1,000,000:1. The amount or ratio of repaired target polynucleotide or polypeptide can be determined by any method known in the art, including but not limited to western blot, northern blot, Southern blot, PCR, sequencing, mass spectrometry, flow cytometry, immunohistochemistry, immunofluorescence, fluorescence in situ hybridization, next generation sequencing, immunoblot, and ELISA.

20 **[0189]** Administration of the rAAV vectors, rAAV viral vectors, compositions or pharmaceutical compositions of this disclosure can be effected in one dose, continuously or intermittently throughout the course of treatment. In some aspects, the rAAV vectors, rAAV viral vectors, compositions, or pharmaceutical compositions of this disclosure are parenterally administered by injection, infusion, or implantation. In some aspects, the rAAV vectors, rAAV viral vectors, compositions, or pharmaceutical compositions of this disclosure are administered repeatedly. In some aspects, the rAAV vectors, rAAV viral vectors, compositions, or pharmaceutical compositions of this disclosure are administered in a single dose.

30 **[0190]** In some aspects, the rAAV viral vectors of this disclosure show enhanced tropism for cardiac tissue.

[0191] Methods of Manufacture

[0192] A variety of approaches may be used to produce rAAV viral vectors of the present disclosure. In some aspects, packaging is achieved by using a helper virus or helper plasmid and a cell line. The helper virus or helper plasmid contains elements and sequences that facilitate viral vector production. In another aspect, the helper plasmid is stably  
5 incorporated into the genome of a packaging cell line, such that the packaging cell line does not require additional transfection with a helper plasmid.

[0193] In some aspects, rAAV viral vectors of the present disclosure may be manufactured according to a baculovirus infection of insect cells.

10 [0194] In some aspects, the cell is a packaging or helper cell line. In some aspects, the helper cell line is eukaryotic cell; for example, an HEK 293 cell or 293T cell. In some aspects, the helper cell is a yeast cell or an insect cell.

[0195] In some aspects, the cell comprises a nucleic acid encoding a tetracycline activator protein; and a promoter that regulates expression of the tetracycline activator protein. In some aspects, the promoter that regulates expression of the tetracycline activator  
15 protein is a constitutive promoter. In some aspects, the promoter is a phosphoglycerate kinase promoter (PGK) or a CMV promoter.

[0196] A helper plasmid may comprise, for example, at least one viral helper DNA sequence derived from a replication-incompetent viral genome encoding in trans all virion  
20 proteins required to package a replication incompetent AAV, and for producing virion proteins capable of packaging the replication-incompetent AAV at high titer, without the production of replication-competent AAV.

[0197] Helper plasmids for packaging AAV are known in the art, see, e.g., U.S. Patent Pub. No. 2004/0235174 A1, incorporated herein by reference. As stated therein, an  
25 AAV helper plasmid may contain as helper virus DNA sequences, by way of non-limiting example, the Ad5 genes E2A, E4 and VA, controlled by their respective original promoters or by heterologous promoters. AAV helper plasmids may additionally contain an expression cassette for the expression of a marker protein such as a fluorescent protein to permit the simple detection of transfection of a desired target cell.

30 [0198] The disclosure provides methods of producing rAAV viral vectors comprising transfecting a packaging cell line with any one of the AAV helper plasmids disclosed herein; and any one of the rAAV vectors disclosed herein. In some aspects, the AAV helper plasmid and rAAV vector are co-transfected into the packaging cell line. In

some aspects, the cell line is a mammalian cell line, for example, human embryonic kidney (HEK) 293 cell line. The disclosure provides cells comprising any one of the rAAV vectors and/or rAAV viral vectors disclosed herein.

[0199] As used herein, the term "helper" in reference to a virus or plasmid refers to a virus or plasmid used to provide the additional components necessary for replication and packaging of any one of the rAAV vectors disclosed herein. The components encoded by a helper virus may include any genes required for virion assembly, encapsidation, genome replication, and/or packaging. For example, the helper virus or plasmid may encode necessary enzymes for the replication of the viral genome. Non-limiting examples of helper viruses and plasmids suitable for use with AAV constructs include pHELP (plasmid), adenovirus (virus), or herpesvirus (virus). In some aspects, the pHELP plasmid may be the pHELPK plasmid, wherein the ampicillin expression cassette is exchanged with a kanamycin expression cassette.

[0200] As used herein, a packaging cell (or a helper cell) is a cell used to produce viral vectors. Producing recombinant AAV viral vectors requires Rep and Cap proteins provided in *trans* as well as gene sequences from Adenovirus that help AAV replicate. In some aspects, Packaging/helper cells contain a plasmid is stably incorporated into the genome of the cell. In other aspects, the packaging cell may be transiently transfected. Typically, a packaging cell is a eukaryotic cell, such as a mammalian cell or an insect cell.

## 20 Kits

[0201] The isolated polynucleotides, rAAV vectors, rAAV viral vectors, compositions, and/or pharmaceutical compositions described herein may be assembled into pharmaceutical or diagnostic or research kits to facilitate their use in therapeutic, diagnostic, or research applications. In some aspects, the kits of the present disclosure include any one of the isolated polynucleotides, rAAV vectors, rAAV viral vectors, compositions, pharmaceutical compositions, host cells, isolated tissues, as described herein.

[0202] In some aspects, a kit further comprises instructions for use. Specifically, such kits may include one or more agents described herein, along with instructions describing the intended application and the proper use of these agents. In some aspects, the kit may include instructions for mixing one or more components of the kit and/or isolating and mixing a sample and applying to a subject. In some aspects, agents in a kit are in a pharmaceutical formulation and dosage suitable for a particular application and for a method

of administration of the agents. Kits for research purposes may contain the components in appropriate concentrations or quantities for running various experiments.

[0203] The kit may be designed to facilitate use of the methods described herein and can take many forms. Each of the compositions of the kit, where applicable, may be provided in liquid form (e.g., in solution), or in solid form, (e.g., a dry powder). In certain cases, some of the compositions may be constitutable or otherwise processable (e.g., to an active form), for example, by the addition of a suitable solvent or other species (for example, water or a cell culture medium), which may or may not be provided with the kit. In some aspects, the compositions may be provided in a preservation solution (e.g., cryopreservation solution). Non-limiting examples of preservation solutions include DMSO, paraformaldehyde, and CryoStor® (Stem Cell Technologies, Vancouver, Canada). In some aspects, the preservation solution contains an amount of metalloprotease inhibitors.

[0204] In some aspects, the kit contains any one or more of the components described herein in one or more containers. Thus, in some aspects, the kit may include a container housing agents described herein. The agents may be in the form of a liquid, gel or solid (powder). The agents may be prepared sterilely, packaged in a syringe and shipped refrigerated. Alternatively, they may be housed in a vial or other container for storage. A second container may have other agents prepared sterilely. Alternatively, the kit may include the active agents premixed and shipped in a syringe, vial, tube, or other container. The kit may have one or more or all of the components required to administer the agents to a subject, such as a syringe, topical application devices, or IV needle tubing and bag.

#### Further definitions

[0205] Unless the context indicates otherwise, it is specifically intended that the various features of the invention described herein can be used in any combination. Moreover, the disclosure also contemplates that, in some aspects, any feature or combination of features set forth herein can be excluded or omitted. To illustrate, if the specification states that a complex comprises components A, B and C, it is specifically intended that any of A, B or C, or a combination thereof, can be omitted and disclaimed singularly or in any combination.

[0206] Unless explicitly indicated otherwise, all specified aspects, embodiments, features, and terms intend to include both the recited aspect, embodiment, feature, or term and biological equivalents thereof.



[0207] The practice of the present technology will employ, unless otherwise indicated, conventional techniques of organic chemistry, pharmacology, immunology, molecular biology, microbiology, cell biology and recombinant DNA, which are within the skill of the art. See, *e.g.*, Sambrook, Fritsch and Maniatis, *Molecular Cloning: A Laboratory Manual*, 2nd edition (1989); *Current Protocols In Molecular Biology* (F. M. Ausubel, et al. eds., (1987)); the series *Methods in Enzymology* (Academic Press, Inc.): *PCR 2: A Practical Approach* (M.J. MacPherson, B.D. Hames and G.R. Taylor eds. (1995)), Harlow and Lane, eds. (1988) *Antibodies, a Laboratory Manual*, and *Animal Cell Culture* (R.I. Freshney, ed. (1987)).

10 [0208] As used herein, the term "comprising" is intended to mean that the compositions and methods include the recited elements, but do not exclude others. As used herein, the transitional phrase "consisting essentially of" (and grammatical variants) is to be interpreted as encompassing the recited materials or steps and those that do not materially affect the basic and novel characteristic(s) of the recited embodiment. Thus, the term  
15 "consisting essentially of" as used herein should not be interpreted as equivalent to "comprising." "Consisting of" shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions disclosed herein. Aspects defined by each of these transition terms are within the scope of the present disclosure. In each instance herein any of the terms "comprising," "consisting essentially  
20 of," and "consisting of" can be replaced with either of the other two terms, while retaining their ordinary meanings.

[0209] When introducing elements of the present invention or the preferred embodiment(s) thereof, the articles "a", "an", "the" and "said" are intended to mean that there are one or more of the elements. The terms "comprising", "including" and "having"  
25 are intended to be inclusive and mean that there may be additional elements other than the listed elements.

[0210] It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have  
30 specifically disclosed all the possible sub-ranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that

range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range. Values or ranges may be also be expressed herein as “about,” from “about” one particular value, and/or to “about” another particular value. When such values or ranges are expressed, other embodiments disclosed include the specific value recited, from the one particular value, and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another embodiment. It will be further understood that there are a number of values disclosed therein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. In embodiments, “about” can be used to mean, for example, within 10% of the recited value, within 5% of the recited value, or within 2% of the recited value.

**[0211]** All numerical designations, e.g., pH, temperature, time, concentration, and molecular weight, including ranges, are approximations which are varied (+) or (-) by increments of 1.0 or 0.1, as appropriate, or, alternatively, by a variation of +/- 15%, 10%, 5%, 2%. It is to be understood, although not always explicitly stated, that all numerical designations are preceded by the term "about". It also is to be understood, although not always explicitly stated, that the reagents described herein are merely exemplary and that equivalents of such are known in the art. The term "about," as used herein when referring to a measurable value such as an amount or concentration and the like, is meant to encompass variations of 20%, 10%, 5%, 1%, 0.5%, or even 0.1% of the specified amount.

**[0212]** The terms "acceptable," "effective," or "sufficient" when used to describe the selection of any components, ranges, dose forms, etc. disclosed herein intend that said component, range, dose form, etc. is suitable for the disclosed purpose.

**[0213]** Also, as used herein, "and/or" refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative ("or").

**[0214]** The term “combination” refers to either a fixed combination in one dosage unit form, or a kit of parts for the combined administration where one or more active compounds and a combination partner (e.g., another drug as explained below, also referred to as “therapeutic agent” or “co-agent”) may be administered independently at the same time or separately within time intervals. In some circumstances, the combination partners show a cooperative, e.g., synergistic effect. The terms “co-administration” or “combined administration” or the like as utilized herein are meant to encompass administration of the

selected combination partner to a single subject in need thereof (e.g., a patient), and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.

[0215] The term “pharmaceutical combination” as used herein means a product that results from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients. The term “fixed combination” means that the active ingredients, e.g., a compound and a combination partner, are both administered to a patient simultaneously in the form of a single entity or dosage. The term “non-fixed combination” means that the active ingredients, e.g., a compound and a combination partner, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the two compounds in the body of the patient. The latter also applies to cocktail therapy, e.g., the administration of three or more active ingredients.

[0216] Unless specifically recited, the term "host cell" includes a eukaryotic host cell, including, for example, fungal cells, yeast cells, higher plant cells, insect cells and mammalian cells. Non-limiting examples of eukaryotic host cells include simian, bovine, porcine, murine, rat, avian, reptilian and human, e.g., HEK293 cells and 293T cells.

[0217] The term "isolated" as used herein refers to molecules or biologicals or cellular materials being substantially free from other materials.

[0218] A “sequence” of a nucleic acid refers to the order and identity of nucleotides in the nucleic acid. A sequence is typically read in the 5' to 3' direction. The terms “identical” or percent “identity” in the context of two or more nucleic acid or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence, e.g., as measured using one of the sequence comparison algorithms available to persons of skill or by visual inspection. Exemplary algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST programs, which are described in, e.g., Altschul et al. (1990) “Basic local alignment search tool” J. Mol. Biol. 215:403-410, Gish et al. (1993) “Identification of protein coding regions by database similarity search” Nature Genet. 3:266-272, Madden et al. (1996) “Applications of network BLAST server” Meth. Enzymol. 266:131-141, Altschul et al. (1997) “Gapped BLAST and PSI-BLAST: a new generation

of protein database search programs” Nucleic Acids Res. 25:3389-3402, and Zhang et al. (1997) “PowerBLAST: A new network BLAST application for interactive or automated sequence analysis and annotation” Genome Res. 7:649-656, which are each incorporated by reference. Many other optimal alignment algorithms are also known in the art and are optionally utilized to determine percent sequence identity.

**[0219]** As used herein, the terms "nucleic acid sequence" and "polynucleotide" are used interchangeably to refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. Thus, this term includes, but is not limited to, single-, double-, or multi- stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or a polymer comprising, consisting essentially of, or consisting of purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases.

**[0220]** “Nucleic acid” or “nucleic acid molecule” refers to a multimeric compound comprising two or more covalently bonded nucleosides or nucleoside analogs having nitrogenous heterocyclic bases, or base analogs, where the nucleosides are linked together by phosphodiester bonds or other linkages to form a polynucleotide. Nucleic acids include RNA, DNA, or chimeric DNA-RNA polymers or oligonucleotides, and analogs thereof. A nucleic acid backbone can be made up of a variety of linkages, including one or more of sugar- phosphodiester linkages, peptide-nucleic acid bonds, phosphorothioate linkages, methylphosphonate linkages, or combinations thereof. Sugar moieties of the nucleic acid can be ribose, deoxyribose, or similar compounds having known substitutions (e.g. 2'-methoxy substitutions and 2'-halide substitutions). Nitrogenous bases can be conventional bases (A, G, C, T, U) or analogs thereof (e.g., inosine, 5-methylisocytosine, isoguanine). A nucleic acid can comprise only conventional sugars, bases, and linkages as found in RNA and DNA, or can include conventional components and substitutions (e.g., conventional bases linked by a 2'- methoxy backbone, or a nucleic acid including a mixture of conventional bases and one or more base analogs). Nucleic acids can include “locked nucleic acids” (LNA), in which one or more nucleotide monomers have a bicyclic furanose unit locked in an RNA mimicking sugar conformation, which enhances hybridization affinity toward complementary sequences in single- stranded RNA (ssRNA), single-stranded DNA (ssDNA), or double-stranded DNA (dsDNA). Nucleic acids can include modified bases to alter the function or behavior of the nucleic acid (e.g., addition of a 3'-terminal dideoxynucleotide to block additional nucleotides from being added to the nucleic

acid). Synthetic methods for making nucleic acids in vitro are well known in the art although nucleic acids can be purified from natural sources using routine techniques. Nucleic acids can be single-stranded or double-stranded.

[0221] A "gene" refers to a polynucleotide containing at least one open reading  
5 frame (ORF) that is capable of encoding a particular polypeptide or protein. A "gene product" or, alternatively, a "gene expression product" refers to the amino acid sequence (e.g., peptide or polypeptide) generated when a gene is transcribed and translated.

[0222] A nucleic acid is typically single-stranded or double-stranded and will  
10 generally contain phosphodiester bonds, although in some cases, as outlined, herein, nucleic acid analogs are included that may have alternate backbones, including, for example and without limitation, phosphoramidate (Beaucage et al. (1993) *Tetrahedron* 49(10):1925 and references therein; Letsinger (1970) *J. Org. Chem.* 35:3800; Sprinzl et al. (1977) *Eur. J. Biochem.* 81:579; Letsinger et al. (1986) *Nucl. Acids Res.* 14: 3487; Sawai et al. (1984) *Chem. Lett.* 805; Letsinger et al. (1988) *J. Am. Chem. Soc.* 110:4470; and Pauwels et al.  
15 (1986) *Chemica Scripta* 26: 1419, which are each incorporated by reference), phosphorothioate (Mag et al. (1991) *Nucleic Acids Res.* 19:1437; and U.S. Pat. No. 5,644,048, which are both incorporated by reference), phosphorodithioate (Briu et al. (1989) *J. Am. Chem. Soc.* 111:2321, which is incorporated by reference), O-methylphosphoroamidite linkages (see Eckstein, *Oligonucleotides and Analogues: A  
20 Practical Approach*, Oxford University Press (1992), which is incorporated by reference), and peptide nucleic acid backbones and linkages (see, Egholm (1992) *J. Am. Chem. Soc.* 114:1895; Meier et al. (1992) *Chem. Int. Ed. Engl.* 31:1008; Nielsen (1993) *Nature* 365:566; and Carlsson et al. (1996) *Nature* 380:207, which are each incorporated by reference). Other analog nucleic acids include those with positively charged backbones (Denpcy et al. (1995)  
25 *Proc. Natl. Acad. Sci. USA* 92:6097, which is incorporated by reference); non-ionic backbones (U.S. Pat. Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; Angew (1991) *Chem. Intl. Ed. English* 30: 423; Letsinger et al. (1988) *J. Am. Chem. Soc.* 110:4470; Letsinger et al. (1994) *Nucleoside & Nucleotide* 13:1597; Chapters 2 and 3, *ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research"*, Ed. Y. S.  
30 Sanghvi and P. Dan Cook; Mesmaeker et al. (1994) *Bioorganic & Medicinal Chem: Lett.* 4: 395; Jeffs et al. (1994) *J. Biomolecular NMR* 34:17; and *Tetrahedron Lett.* 37:743 (1996), which are each incorporated by reference) and non-ribose backbones, including those described in U.S. Pat. Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, *ASC*

Symposium Series 580, Carbohydrate Modifications in Antisense Research, Ed. Y. S. Sanghvi and P. Dan Cook, which references are each incorporated by reference. Nucleic acids containing one or more carbocyclic sugars are also included within the definition of nucleic acids (see Jenkins et al. (1995) Chem. Soc. Rev. pp 169-176, which is incorporated  
5 by reference). Several nucleic acid analogs are also described in, e.g., Rawls, C & E News Jun. 2, 1997 page 35, which is incorporated by reference. These modifications of the ribose-phosphate backbone may be done to facilitate the addition of additional moieties such as labels, or to alter the stability and half-life of such molecules in physiological environments.

**[0223]** In addition to these naturally occurring heterocyclic bases that are typically  
10 found in nucleic acids (e.g., adenine, guanine, thymine, cytosine, and uracil), nucleic acid analogs also include those having non-naturally occurring heterocyclic or modified bases, many of which are described, or otherwise referred to, herein. In particular, many non-naturally occurring bases are described further in, e.g., Seela et al. (1991) *Helv. Chim. Acta* 74:1790, Grein et al. (1994) *Bioorg. Med. Chem. Lett.* 4:971-976, and Seela et al. (1999)  
15 *Helv. Chim. Acta* 82:1640, which are each incorporated by reference. To further illustrate, certain bases used in nucleotides that act as melting temperature (TO modifiers are optionally included. For example, some of these include 7-deazapurines (e.g., 7-deazaguanine, 7-deazaadenine, etc.), pyrazolo[3,4-d]pyrimidines, propynyl-dN (e.g., propynyl-dU, propynyl-dC, etc.), and the like. See, e.g., U.S. Pat. No. 5,990,303, entitled  
20 "SYNTHESIS OF 7-DEAZA-2'-DEOXYGUANOSINE NUCLEOTIDES," which issued Nov. 23, 1999 to Seela, which is incorporated by reference. Other representative heterocyclic bases include, e.g., hypoxanthine, inosine, xanthine; 8-aza derivatives of 2-aminopurine, 2,6-diaminopurine, 2-amino-6-chloropurine, hypoxanthine, inosine and xanthine; 7-deaza-8-aza derivatives of adenine, guanine, 2-aminopurine, 2,6-  
25 diaminopurine, 2-amino-6- chloropurine, hypoxanthine, inosine and xanthine; 6-azacytosine; 5-fluorocytosine; 5- chlorocytosine; 5-iodocytosine; 5-bromocytosine; 5-methylcytosine; 5-propynylcytosine; 5- bromovinyluracil; 5-fluorouracil; 5-chlorouracil; 5-iodouracil; 5-bromouracil; 5- trifluoromethyluracil; 5-methoxymethyluracil; 5-ethynyluracil; 5-propynyluracil, and the like.

**[0224]** Examples of modified bases and nucleotides are also described in, e.g., U.S.  
30 Pat. No. 5,484,908, entitled "OLIGONUCLEOTIDES CONTAINING 5-PROPYNYL

[0225] PYRIMIDINES,” issued Jan. 16, 1996 to Froehler et al., U.S. Pat. No. 5,645,985, entitled “ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES,” issued Jul. 8, 1997 to Froehler et al., U.S. Pat. No. 5,830,653, entitled “METHODS OF USING  
5 OLIGOMERS CONTAINING MODIFIED PYRIMIDINES,” issued Nov. 3, 1998 to Froehler et al., U.S. Pat. No. 6,639,059, entitled “SYNTHESIS OF [2.2.1]BICYCLO NUCLEOSIDES,” issued Oct. 28, 2003 to Kochkine et al., U.S. Pat. No. 6,303,315, entitled “ONE STEP SAMPLE PREPARATION AND DETECTION OF NUCLEIC ACIDS IN COMPLEX BIOLOGICAL SAMPLES,” issued Oct. 16, 2001 to Skouv, and U.S. Pat.  
10 Application Pub. No. 2003/0092905, entitled “SYNTHESIS OF [2.2.1]BICYCLO NUCLEOSIDES,” by Kochkine et al. that published May 15, 2003, which are each incorporated by reference.

[0226] As used herein, "expression" refers to the two-step process by which polynucleotides are transcribed into mRNA and/or the process by which the transcribed  
15 mRNA is subsequently translated into peptides, polypeptides, or proteins. If the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in a eukaryotic cell.

[0227] "Under transcriptional control" is a term well understood in the art and indicates that transcription of a polynucleotide sequence, usually a DNA sequence, depends  
20 on its being operatively linked to an element that contributes to the initiation of, or promotes, transcription. "Operatively linked" intends that the polynucleotides are arranged in a manner that allows them to function in a cell. In one aspect, promoters can be operatively linked to the downstream sequences.

[0228] The term "encode" as it is applied to polynucleotides and/or nucleic acid  
25 sequences refers to a polynucleotide and/or nucleic acid sequence which is said to "encode" a polypeptide if, in its native state or when manipulated by methods well known to those skilled in the art, it can be transcribed to produce the mRNA for the polypeptide and/or a fragment thereof. The antisense strand is the complement of such a nucleic acid, and the encoding sequence can be deduced therefrom.

[0229] The term "protein", "peptide" and "polypeptide" are used interchangeably  
30 and in their broadest sense to refer to a compound of two or more subunits of amino acids, amino acid analogs or peptidomimetics. The subunits may be linked by peptide bonds. In another aspect, the subunit may be linked by other bonds, e.g., ester, ether, etc. A protein or

peptide must contain at least two amino acids and no limitation is placed on the maximum number of amino acids which may comprise, consist essentially of, or consist of a protein's or peptide's sequence. As used herein the term "amino acid" refers to either natural and/or unnatural or synthetic amino acids, including glycine and both the D and L optical isomers,  
5 amino acid analogs and peptidomimetics.

**[0230]** As used herein, the term "signal peptide" or "signal polypeptide" intends an amino acid sequence usually present at the N-terminal end of newly synthesized secretory or membrane polypeptides or proteins. It acts to direct the polypeptide to a specific cellular location, e.g. across a cell membrane, into a cell membrane, or into the nucleus. In some  
10 aspects, the signal peptide is removed following localization. Examples of signal peptides are well known in the art. Non-limiting examples are those described in U.S. Patent Nos. 8,853,381, 5,958,736, and 8,795,965. In some aspects, the signal peptide can be an IDUA signal peptide.

**[0231]** The terms "equivalent" or "biological equivalent" are used  
15 interchangeably when referring to a particular molecule, biological material, or cellular material and intend those having minimal homology while still maintaining desired structure or functionality. Non-limiting examples of equivalent polypeptides include a polypeptide having at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%  
20 identity or at least about 99% identity to a reference polypeptide (for instance, a wild-type polypeptide); or a polypeptide which is encoded by a polynucleotide having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95% identity, at least about 97% sequence identity or at least about 99% sequence identity to the reference polynucleotide (for instance, a wild-type  
25 polynucleotide).

**[0232]** "Homology" or "identity" or "similarity" refers to sequence similarity between two peptides or between two nucleic acid molecules. Percent identity can be determined by comparing a position in each sequence that may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base  
30 or amino acid, then the molecules are identical at that position. A degree of identity between sequences is a function of the number of matching positions shared by the sequences. "Unrelated" or "non-homologous" sequences share less than 40% identity, less than 25% identity, with one of the sequences of the present disclosure. Alignment



and percent sequence identity may be determined for the nucleic acid or amino acid sequences provided herein by importing said nucleic acid or amino acid sequences into and using ClustalW (available at <https://genome.jp/tools-bin/clustalw/>). For example, the ClustalW parameters used for performing the protein sequence alignments found  
5 herein were generated using the Gonnet (for protein) weight matrix. In some aspects, the ClustalW parameters used for performing nucleic acid sequence alignments using the nucleic acid sequences found herein are generated using the ClustalW (for DNA) weight matrix.

**[0233]** As used herein, amino acid modifications may be amino acid substitutions, amino acid deletions or amino acid insertions. Amino acid substitutions may be conservative amino acid substitutions or non-conservative amino acid substitutions. A conservative replacement (also called a conservative mutation, a conservative substitution or a conservative variation) is an amino acid replacement in a protein that changes a given amino acid to a different amino acid with similar biochemical properties (e.g., charge,  
15 hydrophobicity or size). As used herein, "conservative variations" refer to the replacement of an amino acid residue by another, biologically similar residue. Examples of conservative variations include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another; or the substitution of one charged or polar residue for another, such as the substitution of arginine for lysine, glutamic acid for aspartic acid,  
20 glutamine for asparagine, and the like. Other illustrative examples of conservative substitutions include the changes of: alanine to serine; asparagine to glutamine or histidine; aspartate to glutamate; cysteine to serine; glycine to proline; histidine to asparagine or glutamine; lysine to arginine, glutamine, or glutamate; phenylalanine to tyrosine, serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or  
25 phenylalanine; and the like.

**[0234]** A polynucleotide disclosed herein can be delivered to a cell or tissue using a gene delivery vehicle. "Gene delivery," "gene transfer," "transducing," and the like as used herein, are terms referring to the introduction of an exogenous polynucleotide (sometimes referred to as a "transgene") into a host cell, irrespective of  
30 the method used for the introduction. Such methods include a variety of well-known techniques such as vector-mediated gene transfer (by, e.g., viral infection/transfection, or various other protein-based or lipid-based gene delivery complexes) as well as techniques facilitating the delivery of "naked" polynucleotides (such as electroporation,

"gene gun" delivery and various other techniques used for the introduction of polynucleotides). The introduced polynucleotide may be stably or transiently maintained in the host cell. Stable maintenance typically requires that the introduced polynucleotide either contains an origin of replication compatible with the host cell or  
5 integrates into a replicon of the host cell such as an extrachromosomal replicon (e.g., a plasmid) or a nuclear or mitochondrial chromosome. A number of vectors are known to be capable of mediating transfer of genes to mammalian cells, as is known in the art and described herein.

[0235] A "plasmid" is a DNA molecule that is typically separate from and capable of replicating independently of the chromosomal DNA. In many cases, it is circular and double-stranded. Plasmids provide a mechanism for horizontal gene transfer within a population of microbes and typically provide a selective advantage under a given environmental state. Plasmids may carry genes that provide resistance to naturally occurring antibiotics in a competitive environmental niche, or, alternatively, the proteins produced  
15 may act as toxins under similar circumstances. It is known in the art that while plasmid vectors often exist as extrachromosomal circular DNA molecules, plasmid vectors may also be designed to be stably integrated into a host chromosome either randomly or in a targeted manner, and such integration may be accomplished using either a circular plasmid or a plasmid that has been linearized prior to introduction into the host cell.

[0236] "Plasmids" used in genetic engineering are called "plasmid vectors". Many plasmids are commercially available for such uses. The gene to be replicated is inserted into copies of a plasmid containing genes that make cells resistant to particular antibiotics, and a multiple cloning site (MCS, or polylinker), which is a short region containing several commonly used restriction sites allowing the easy insertion of DNA fragments at this  
25 location. Another major use of plasmids is to make large amounts of proteins. In this case, researchers grow bacteria or eukaryotic cells containing a plasmid harboring the gene of interest, which can be induced to produce large amounts of proteins from the inserted gene.

[0237] In aspects where gene transfer is mediated by a DNA viral vector, such as an adenovirus (Ad) or adeno-associated virus (AAV), a vector construct refers to the polynucleotide comprising, consisting essentially of, or consisting of the viral genome or  
30 part thereof, and a transgene.

[0238] The term "tissue" is used herein to refer to tissue of a living or deceased organism or any tissue derived from or designed to mimic a living or deceased organism.

The tissue may be healthy, diseased, and/or have genetic mutations. The biological tissue may include any single tissue (e.g., a collection of cells that may be interconnected), or a group of tissues making up an organ or part or region of the body of an organism. The tissue may comprise, consist essentially of, or consist of a homogeneous cellular material or it may  
5 be a composite structure such as that found in regions of the body including the thorax which for instance can include lung tissue, skeletal tissue, and/or muscle tissue. Exemplary tissues include, but are not limited to those derived from liver, lung, thyroid, skin, pancreas, blood vessels, bladder, kidneys, brain, biliary tree, duodenum, abdominal aorta, iliac vein, heart and intestines, including any combination thereof.

## 10 **Examples**

### *Example 1*

**[0239]** Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a predominantly genetic-based heart disease characterized by right but also recently left ventricular dysfunction, fibrofatty replacement of the myocardium leading to ventricular  
15 arrhythmias and sudden cardiac death in young people and athletes (1). ARVC is responsible for 10% of sudden cardiac deaths in people  $\leq 65$  years of age and 24% in people  $\leq 30$  years of age (2, 3). ARVC is thought to occur in 1 in 1000-5000 people, although the prevalence may be higher as some patients are undiagnosed or misdiagnosed due to poor diagnostic markers (4, 5). Growing evidence also reveals earlier onset since pediatric populations  
20 ranging from infants to children in their teens are also particularly vulnerable to ARVC (6-10), highlighting the critical need to identify and treat patients at an earlier stage of the disease.

**[0240]** Over the last decade, ARVC has been recognized as a disease of the cardiac desmosome (specialized cell-cell junction) as 40-50% cases are linked to  
25 mutations/deficiencies in multiple genes associated with the desmosome (desmoglein-2, desmocollin-2, plakoglobin, plakophilin-2, desmoplakin), thus, NOT considered a single gene disease (11). Critical to the disease is that mutations/deficiencies in one component of the desmosomal complex has devastating cascading effects on other members of the desmosomal complex as well as other parts of the cardiac cell-cell junction (fascia adherens  
30 junction linked to contractile machinery and gap junctions linked to electrical coupling), which drives cardiac structural and electrical deficits underlying ARVC. The hierarchal dissolution of the desmosomal complex alongside functionally important neighboring cell junctional components, highlight the need for strategies that target restorative effects on the

entire cardiac cell-cell junctional complex, and not just the desmosome itself. The disclosure provides studies demonstrating a single gene strategy (plakophilin-2) to reassemble the cardiac cell-cell junction complex and prevent ARVC disease development.

[0241] This invention is a targeted gene therapy, which delivers PKP2 cDNA and ultimately increases PKP2 protein levels in the heart (Fig. 1A-C). This gene therapy utilizes a cardiotropic AAV serotype 9 (AAV9) or AAVrh10, as well as cardiac-specific promoter cardiac troponin T to drive cardiomyocyte-specific expression (Fig. 1B-C; Fig. 8A). PKP2 expression can effectively reassemble the cardiac desmosome (Fig. 2; Fig. 3A-B; Fig. 6F; Fig. 7B; Fig. 8A,8E), which serves as a molecular scaffold to circumvent cardiac cell-cell junction defects underlying ARVC. PKP2 stabilizes the desmosome as well as other cell-cell junction complexes (gap junction and fascia-adherens junction), which are downstream cascading defects underlying disease progression (Fig. 2; Fig. 3A-B; Fig. 6F; Fig. 7B; Fig. 8A,8E). AAV9 PKP2 gene therapy can function as a prophylaxis with early delivery before disease development or to halt disease progression in patients with existing disease (Fig. 3C; Fig. 4; Fig. 5; Fig. 6A-F; Fig. 7D,7E; Fig. 8B-D).

[0242] This disclosure provides studies which show a treatment with AAV vectors comprising PKP2 in PKP2 mutant neonatal cardiomyocytes improved cell-cell junction protein levels (PKP2, DSP, DSG2, JUP, CX43) (Fig. 1A, Fig. 2). This disclosure provides a AAV9 or AAVrh10 vectors comprising a sequence encoding PKP2, which can successfully express PKP2 under the control of a cardiac troponin T promoter in the heart *in vivo* (Fig. 1B-C; Fig. 8A). At postnatal day 2 in PKP2 mutant mice, a single intraperitoneal injection of  $5 \times 10^{11}$  viral particles of AAV9 PKP2 was performed (Fig. 3). At 4 weeks post-injection heart lysates were analyzed via western blot and found that AAV9 PKP2 administration could improve levels of cell-cell junction proteins (PKP2, DSP, DSG2, JUP, CX43) (FIG. 3B). Early AAV9 PKP2 injection could also prevent ARVC disease development at 4 weeks of age (FIG. 3C), as there was preservation of cardiac mechanical and electrical function, significantly less fibrosis in myocardium, and prolonged survival (Fig. 4; Fig. 5; Fig. 6A). Cell-cell junction protein levels, cardiac mechanical function, and cardiac electrical function were still preserved 6 months post-AAV9 PKP2 injection (Fig. 6B-6F), highlighting a durable impact of PKP2 gene therapy on ARVC disease development. PKP2 mutant mice were also treated with AAV9 PKP2 at a time point where all disease features were present (4 weeks of age), and showed an improvement in cardiac cell-cell junction proteins (PKP2, DSP, DSG2, JUP, N-Cad) and cardiac mechanical

function (approximately 15% improvement in LV/RV ejection fractions) 2 weeks post-AAV9 PKP2 injection in PKP2 mutant mice compared to PKP2 mutant mice receiving AAV9 GFP (Fig. 7).

[0243] Studies with an AAVrh10 encapsidated PKP2 rAAV vector were also  
5 conducted. These studies demonstrate that AAV vectors of the disclosure, including AAV9  
and AAVrh10 vector serotypes, can stably express human PKP2 protein in adult mouse  
heart and circumvent ARVC disease outcomes in PKP2 Hom mice. FIG. 8A shows a  
western blot analysis that hPKP2 can be expressed as early as 10 days in hearts of adult wild  
10 type control mice using AAV9 at a dose of  $5 \times 10^{13}$  vg/kg when compared to uninjected wild  
type controls (note higher migrating sized band corresponding to hPKP2 versus endogenous,  
lower migrating band corresponding to mouse PKP2). Western blot analysis further shows  
that hPKP2 expression gets more robust at 21 days post-infection in hearts of adult PKP2  
heterozygous (HET) mutant mice using AAVrh10 at a dose of  $5 \times 10^{13}$  vg/kg. The expression  
of hPKP2 could also be detected in the liver albeit at lower levels. Furthermore, AAVrh10-  
15 hPKP2 has “on target” effect as it stabilizes desmoplakin (DSP) levels, an immediate  
binding partner to PKP2 in adult PKP2 Het hearts. DSP levels are restored to control levels  
when compared to wild type control uninjected mice. GAPDH and beta-actin served as  
loading controls. These data show that AAV9 and AAVrh10-PKp2 constructs express in  
the adult mouse heart and that AAVrh10-PKP2 functionally rescues deficits at the cardiac  
20 desmosome in adult PKP2 Het mouse heart.

[0244] Fig. 8B shows the four week survival curve subsequent early administration  
(postnatal day 2 (P2)) of formula and hPKP2 (via AAV9 and AAVrh10) in PKP2 Hom mice.  
Note that AAV9-hPKP2 and AAVrh10-hPKP2 is sufficient to prevent premature death in  
PKP Hom mice that is observed in formula treated PKP2 Hom mice. n=5 AAVrh10 hPKP2,  
25 n=5 Hom-AAV9 PKP2, n=5 formula.

[0245] Fig. 8C shows bar graph analyses of ectopic beats/premature ventricular  
contractions (PVC) in PKP2 Hom mice following surface ECG analysis and early  
administration (P2) of formula and hPKP2 (via AAV9 and AAVrh10). Note that AAV9-  
hPKP2 (n=2) and AAVrh10-hPKP2 (n=4) is sufficient to prevent premature ventricular  
30 contractions in PKP Hom mice as no PVCs were observed in these groups up to 4 weeks of  
age. In contrast, premature death was observed two out of three formula treated PKP2 Hom  
mice at four weeks of age. n=4 AAVrh10 hPKP2, n=2 Hom-AAV9 PKP2, n=3 formula.

[0246] Fig. 8D shows representative cardiac short axis views of magnetic resonance images at end-diastole from wild type control untreated mice, PKP2 Hom treated with formula, PKP2 Hom treated AAV9-hPKP2 and PKP2 Hom treated AAVrh10-hPKP2. Right ventricle (RV) and left ventricle (LV) dimensions are outlined in color in each group at end-diastole. Note the significant reduction in RV and LV dimensions in PKP2 Hom treated with AAVrh10-hPKP2 when compared to formula treated mouse. Note the significant reduction in LV dimensions in PKP2 Hom treated with AAVrh10-hPKP2 when compared to formula treated mouse.

[0247] Fig. 8E shows western blot analysis of PKP2 and cell-cell junction proteins (desmoplakin (DSP), desmoglein-2 (DSG2), connexin43 (Cx43), N-cadherin (NCAD), plakoglobin (JUP) in hearts from wild type control untreated mice, PKP2 Hom treated with formula, PKP2 Hom treated AAV9-hPKP2 and PKP2 Hom treated AAVrh10-hPKP2. Note the significant upregulation in cardiac protein expression of DSP, DSG2, Cx43 (compared to its degraded form found in formula treated mice), JUP in PKP2 Hom treated AAV9-hPKP2 and PKP2 Hom treated AAVrh10-hPKP2, highlighting the prevention of cardiac cell-cell junction dissolution in hPKP2 treated PKP2 Hom hearts. GAPDH is used as a loading control. Note that formula treated mice that died are indicated by an asterisk.

[0248] Therapeutics for ARVC:

- 1) PKP2 could be targeted for therapies for ARVC by generating an adeno-associated viral vector containing the PKP2 cDNA as a means to restore PKP2 levels in ARVC patients.
- 2) PKP2 could be targeted for therapies for ARVC by developing novel direct pharmacological activators of PKP2 as a means to restore PKP2 function in ARVC patients.
- 3) PKP2 could be targeted for therapies for ARVC by developing or utilizing drugs that target pathways downstream of PKP2 function to restore cell-cell junction complex reassembly in ARVC patients.

## REFERENCES

1. Idris, A., S.R. Shah, and K. Park, Right ventricular dysplasia: management and treatment in light of current evidence. *J Community Hosp Intern Med Perspect*, 2018. 8(3): p. 101-106.
- 5 2. Elias Neto, J., et al., Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D) - What We Have Learned after 40 Years of the Diagnosis of This Clinical Entity. *Arq Bras Cardiol*, 2019. 112(1): p. 91-103.
3. Wang, W., C.A. James, and H. Calkins, Diagnostic and therapeutic strategies for arrhythmogenic right ventricular dysplasia/cardiomyopathy patient. *Europace*, 2019. 21(1): p. 9-21.
- 10 4. Sen-Chowdhry, S., et al., Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. *Annu Rev Med*, 2010. 61: p. 233-53
5. Tabib, A., et al., Undetected cardiac lesions cause unexpected sudden cardiac death during occasional sport activity. A report of 80 cases. *Eur Heart J*, 1999. 20(12): p. 900-3.
- 15 6. Tabib, A., et al., Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. *Circulation*, 2003. 108(24): p. 3000-5.
7. Thiene, G., D. Corrado, and C. Basso, Arrhythmogenic right ventricular cardiomyopathy/dysplasia. *Orphanet J Rare Dis*, 2007. 2: p. 45.
- 20 8. Peters, S., M. Trummel, and W. Meyners, Prevalence of right ventricular dysplasia-cardiomyopathy in a non-referral hospital. *Int J Cardiol*, 2004. 97(3): p. 499-501.
9. Nishikawa, T., et al., Programmed cell death in the myocardium of arrhythmogenic right ventricular cardiomyopathy in children and adults. *Cardiovasc Pathol*, 1999. 8(4): p. 185-9.
- 25 10. Wong, A.R., et al., Arrhythmogenic right ventricular cardiomyopathy in an 11-year-old girl and typical echocardiographic features. *Pediatr Cardiol*, 2008. 29(2): p. 427-30.
11. Rey, C., et al., Life-saving automated external defibrillation in a teenager: a case report. *J Med Case Rep*, 2007. 1: p. 76.
- 30 12. Daliento, L., et al., Arrhythmogenic right ventricular cardiomyopathy in young versus adult patients: similarities and differences. *J Am Coll Cardiol*, 1995. 25(3): p. 655-64.

13. Garcia-Gras, E., et al., Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. *J Clin Invest*, 2006. 116(7): p. 2012-21.
14. Marcus, F.I., S. Edson, and J.A. Towbin, Genetics of arrhythmogenic right ventricular cardiomyopathy: a practical guide for physicians. *J Am Coll Cardiol*, 5 2013. 61(19): p. 1945-8.
15. Sen-Chowdhry, S., et al., Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. *Annu Rev Med*, 2010. 61: p. 233-53.
16. Elliott, PM., et al., Definition and treatment of arrhythmogenic cardiomyopathy: an 10 updated expert panel report. *Eur J Heart Fail*, 2019. 8: p. 955-964.
17. Elias Neto, J., et al., Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia (ARVC/D) - What We Have Learned after 40 Years of the Diagnosis of This Clinical Entity. *Arq Bras Cardiol*, 2019. 112(1): p. 91-103.

15



## We Claim:

1. A recombinant adeno-associated virus (rAAV) vector comprising in 5' to 3' direction:
  - a) a first AAV ITR sequence;
  - b) a promoter sequence;
  - c) a transgene nucleic acid molecule, wherein the transgene nucleic acid molecule comprises a nucleic acid sequence encoding for a plakophilin-2 (PKP2) polypeptide;
  - d) a post-transcriptional regulatory element;
  - e) a polyA sequence; and
  - f) a second AAV ITR sequence.
2. An rAAV vector comprising the nucleic acid sequence set forth in SEQ ID NO: 9, SEQ ID NO: 18, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 29, or SEQ ID NO: 30.
3. The rAAV vector of claim 1, wherein the PKP2 polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 13.
4. The rAAV vector of any one of the preceding claims, wherein the nucleic acid sequence encoding for a PKP2 polypeptide comprises the nucleic acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 14.
5. The rAAV vector of any one of the preceding claims, wherein the first AAV ITR sequence comprises the nucleic acid sequence set forth in SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 15, SEQ ID NO: 15, SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO: 25.
6. The rAAV vector of any one of the preceding claims, wherein the second AAV ITR sequence comprises the nucleic acid sequence set forth in SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 15, SEQ ID NO: 15, SEQ ID NO: 19, SEQ ID NO: 20, or SEQ ID NO: 25.

7. The rAAV vector of any one of the preceding claims, wherein the promoter sequence is a cardiac-specific promoter sequence.
8. The rAAV vector of any one of the preceding claims, wherein the promoter sequence comprises a Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), a cytomegalovirus (CMV) promoter, an SV40 promoter, a dihydrofolate reductase promoter, a beta-actin promoter, a phosphoglycerol kinase (PGK) promoter, a U6 promoter, an H1 promoter, a CAG promoter, a hybrid chicken  $\beta$ -actin promoter, an MeCP2 promoter, an EF1 promoter, a ubiquitous chicken  $\beta$ -actin hybrid (CBh) promoter, a U1a promoter, a U1b promoter, an MeCP2 promoter, an MeP418 promoter, an MeP426 promoter, a minimal MeCP2 promoter, a VMD2 promoter, an mRho promoter, EFla promoter, Ubc promoter, human  $\beta$ -actin promoter, TRE promoter, Ac5 promoter, Polyhedrin promoter, CaMKIIa promoter, Gal1 promoter, TEF1 promoter, GDS promoter, ADH1 promoter, Ubi promoter, or  $\alpha$ -1-antitrypsin (hAAT) promoter.
9. The rAAV vector of claim 8, wherein the promoter sequence comprises a cardiac troponin T (cTnT) promoter sequence.
10. The rAAV vector of claim 9, wherein the cTnT promoter sequence comprises the nucleic acid sequence set forth in SEQ ID NO: 2.
11. The rAAV vector of any one of the preceding claims, wherein the polyA sequence comprises a rabbit beta-globin polyA sequence.
12. The rAAV vector of claim 11, wherein the rabbit beta-globin polyA sequence comprises the nucleic acid sequence set forth in SEQ ID NO: 6.
13. The rAAV vector of any one of the preceding claims, wherein the post-transcriptional regulatory element is an oPRE post-transcriptional regulatory element.
14. The rAAV vector of claim 13, wherein the oPRE post-transcriptional regulatory element comprises the nucleic acid sequence set forth in SEQ ID NO: 5, SEQ ID NO: 27, or SEQ ID NO: 28.

15. An rAAV vector of any one of the preceding claims, comprising, in the 5' to 3' direction:
- a) a first AAV ITR sequence comprising the nucleic acid sequence set forth in SEQ ID NO: 7;
  - b) a promoter sequence comprising the nucleic acid sequence set forth in SEQ ID NO: 2;
  - c) a transgene nucleic acid molecule, wherein the transgene nucleic acid molecule comprises a nucleic acid sequence encoding for a PKP2 polypeptide, wherein the nucleic acid sequence encoding for a PKP2 polypeptide comprises the nucleic acid sequence set forth in SEQ ID NO: 4;
  - d) a post-transcriptional regulatory element comprising the nucleic acid sequence set forth in SEQ ID NO: 5;
  - e) a polyA sequence comprising the nucleic acid sequence set forth in SEQ ID NO: 6; and
  - f) a second AAV ITR sequence comprising the nucleic acid sequence set forth in SEQ ID NO: 8.
16. An rAAV viral vector comprising
- (i) an AAV capsid protein; and
  - (ii) an rAAV vector of any one of the preceding claims.
17. The rAAV viral vector of claim 16, wherein the AAV capsid protein is an AAV1 capsid protein, an AAV2 capsid protein, an AAV4 capsid protein, an AAV5 capsid protein, an AAV6 capsid protein, an AAV7 capsid protein, an AAV8 capsid protein, an AAV9 capsid protein, an AAV10 capsid protein, an AAV11 capsid protein, an AAV12 capsid protein, an AAV13 capsid protein, an AAVPHP.B capsid protein, an AAVrh74 capsid protein or an AAVrh10 capsid protein.
18. The rAAV viral vector of claim 17, wherein the AAV capsid protein is an AAV9 or AAVrh10 capsid protein.

19. A pharmaceutical composition comprising:
  - a) the rAAV viral vector of any one of claims 16-18; and at least one pharmaceutically acceptable excipient and/or additive.
20. A method for treating a subject having a disease and/or disorder involving a *PKP2* gene, the method comprising administering to the subject at least one therapeutically effective amount of the rAAV viral vector of any one of claims 16-18 or the pharmaceutical composition of claim 19.
21. The method of claim 20, wherein the disease and/or disorder involving a *PKP2* gene is a cardiovascular disease characterized by abnormal cardiac cell-cell junction complexes.
22. The method of claim 20, wherein the disease and/or disorder involving a *PKP2* gene is arrhythmogenic right ventricular cardiomyopathy (ARVC).
23. The method of claim 20, wherein the effective amount improves electrical and structural cardiac integrity in the subject.
24. The method of claim 20, wherein the effective amount rescues and reassembles cell-cell junction proteins in the subject.
25. The method of claim 20, wherein the effective amount improves cardiac function in the subject.
26. The method of claim 20, wherein the effective amount preserves electrical and structural integrity to prevent ARVC in the subject.
27. The method of any one of claims 20-26, wherein the rAAV viral vector or the pharmaceutical composition is administered to the subject at a dose ranging from about  $1.0 \times 10^{12}$  vg/kg to about  $2.5 \times 10^{14}$  vg/kg .

28. The method of claim 27, wherein the rAAV viral vector or the pharmaceutical composition is administered to the subject at a dose ranging from about  $1.0 \times 10^{12}$  vg/kg to about  $5.0 \times 10^{13}$  vg/kg.

29. The method of any one of claims 20-28, wherein the rAAV viral vector or the pharmaceutical composition is administered to the subject intravenously, intrathecally, intracerebrally, intraventricularly, intranasally, intratracheally, intra-aurally, intra-ocularly, or peri-ocularly, orally, rectally, transmucosally, inhalationally, transdermally, parenterally, subcutaneously, intradermally, intramuscularly, intracisternally, intranervally, intrapleurally, topically, intralymphatically, intracisternally or intranerve.

30. The rAAV viral vector of any one of claims 16-18 or the pharmaceutical composition of claim 18 for use in treating a disease and/or disorder involving a *PKP2* gene in a subject in need thereof.

31. The use of claim 30, wherein the disease and/or disorder involving a *PKP2* gene is ARVC.

32. The use of any one of claims 30-31, wherein the rAAV viral vector or the pharmaceutical composition is for administration to the subject at a dose ranging from about  $1.0 \times 10^{12}$  vg/kg to about  $2.5 \times 10^{14}$  vg/kg.

33. The use of any of claims 30-32, wherein the rAAV viral vector or the pharmaceutical composition is for administration to the subject at a dose ranging from about  $1.0 \times 10^{12}$  vg/kg to about  $5.0 \times 10^{13}$  vg/kg.

34. The use of any one of claims 30-33, wherein the rAAV viral vector or the pharmaceutical composition is for administration to the subject intravenously, intrathecally, intracerebrally, intraventricularly, intranasally, intratracheally, intra-aurally, intra-ocularly, or peri-ocularly, orally, rectally, transmucosally, inhalationally, transdermally, parenterally, subcutaneously, intradermally, intramuscularly, intracisternally, intranervally, intrapleurally, topically, intralymphatically, intracisternally or intranerve.

35. The use of claim 34, wherein the rAAV viral vector or pharmaceutical composition is for administration intravenously.

1/17




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 2



3/17




FIG. 3A




FIG. 3B




FIG. 3C

4/17




FIG. 4A




FIG. 4B




FIG. 4C

5/17




FIG. 4D






FIG. 4E


6/17



**FIG. 5A**



**FIG. 5B**



**FIG. 5C**

7/17

Survival Curve




FIG. 6A

Ctrl

Hom-AAV9 PKP2




FIG. 6B

EF-6 Months




FIG. 6C

8/17




FIG. 6D




FIG. 6E




FIG. 6F

9/17




FIG. 6G

10/17




FIG. 7A




FIG. 7B



11/17




FIG. 7C




FIG. 7D

12/17




FIG. 7E

13/17




FIG. 8A





FIG. 8B







FIG. 8C




Wild type CTRL -UnTreated




End-diastole

PKP2 Hom treated with AAV9 hPKP2




End-diastole

PKP2 Hom treated with Formula





End-diastole

PKP2 Hom treated with AAVrh10-hPKP2



End-diastole

FIG. 8D



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US22/24478

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC - C12N 15/86 (2022.01)  CPC - C12N 15/63; C12N 15/62; C12N 15/86; C12N 2740/16043  According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>  Minimum documentation searched (classification system followed by classification symbols) See Search History document  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched See Search History document  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) See Search History document		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2021/053222 A1 (UCL BUSINESS LTD) 25 March 2021; paragraph [0061]; paragraph [0005]	1, 3, 4/1, 4/3
Y	US 2019/0203212 A1 (MASSACHUSETTS INSTITUTE OF TECHNOLOGY) 04 July 2019; paragraph [0277]; paragraph [0082]	1, 3, 4/1, 4/3
Y	US 2007/0083334 A1 (MINTZ LIAT) 12 April 2007; SEQ ID NO: 915097	3, 4/3
Y	US 2011/0296544 A1 (DOMON BRUNO) 01 December 2011; SEQ ID NO: 1153	4/1, 4/3
A	US 2007/0072175 A1 (COOPER MATTHEW T) 29 March 2007; SEQ ID NO:48204	2, 4/2
A	US 2014/0010861 A1 (MODERNA THERAPEUTICS) 09 January 2014; SEQ ID NO: 22646	2, 4/2
A	US 2014/0206755 A1 (MODERNA THERAPEUTICS, INC.) 24 July 2014; SEQ ID NO: 22647	2, 4/2
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "D" document cited by the applicant in the international application "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 22 June 2022 (22.06.2022)		Date of mailing of the international search report JUL 25 2022
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-8300		Authorized officer Shane Thomas  Telephone No. PCT Helpdesk: 571-272-4300



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US22/24478

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
  - a.  forming part of the international application as filed:
    - in the form of an Annex C/ST.25 text file.
    - on paper or in the form of an image file.
  - b.  furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
  - c.  furnished subsequent to the international filing date for the purposes of international search only:
    - in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
    - on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2.  In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US22/24478

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3.  Claims Nos.: 5-35  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.